{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:37:56Z","timestamp":1787020676911,"version":"build-2736575974"},"reference-count":259,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"DOI":"10.1186\/s12941-025-00830-7","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:34:29Z","timestamp":1761744869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Current infectious disease management challenges in inborn errors of immunity"],"prefix":"10.1186","volume":"24","author":[{"given":"Shuwei","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"830_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13223-022-00662-6","volume":"18","author":"J Quinn","year":"2022","unstructured":"Quinn J, Modell V, Orange JS, Modell F. Growth in diagnosis and treatment of primary immunodeficiency within the global Jeffrey Modell Centers network. Allergy Asthma Clin Immunol. 2022;18:19.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"830_CR2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1080\/1744666X.2020.1801422","volume":"16","author":"H Abolhassani","year":"2020","unstructured":"Abolhassani H, Azizi G, Sharifi L, Yazdani R, Mohsenzadegan M, Delavari S, et al. Global systematic review of primary immunodeficiency registries. Expert Rev Clin Immunol. 2020;16:717\u201332.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"830_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-024-01855-x","volume":"45","author":"S Nikzad","year":"2025","unstructured":"Nikzad S, Johnson R, Scalchunes C, Rider NL. Quantifying the diagnostic odyssey burden among persons with inborn errors of immunity. J Clin Immunol. 2025;45(1):61. https:\/\/doi.org\/10.1007\/s10875-024-01855-x.","journal-title":"J Clin Immunol"},{"issue":"5","key":"830_CR4","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.jaci.2021.04.015","volume":"148","author":"J Thalhammer","year":"2021","unstructured":"Thalhammer J, Kindle G, Nieters A, Rusch S, Sepp\u00e4nen MRJ, Fischer A, Grimbacher B, Edgar D, Buckland M, Mahlaoui N, Ehl S, European Society for Immunodeficiencies Registry Working Party. Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations. J Allergy Clin Immunol. 2021;148(5):1332\u201341.","journal-title":"J Allergy Clin Immunol."},{"key":"830_CR5","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s10875-014-0102-8","volume":"34","author":"L Kobrynski","year":"2014","unstructured":"Kobrynski L, Powell RW, Bowen S. Prevalence and morbidity of primary immunodeficiency diseases, United States 2001\u20132007. J Clin Immunol. 2014;34:954\u201361.","journal-title":"J Clin Immunol."},{"issue":"4","key":"830_CR6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.iac.2015.07.001","volume":"35","author":"N Raje","year":"2015","unstructured":"Raje N, Dinakar C. Overview of immunodeficiency disorders. Immunol Allergy Clin North Am. 2015;35(4):599\u2013623.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"7","key":"830_CR7","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1007\/s10875-022-01352-z","volume":"42","author":"A Bousfiha","year":"2022","unstructured":"Bousfiha A, Moundir A, Tangye SG, Picard C, Jeddane L, Al-Herz W, Rundles CC, Franco JL, Holland SM, Klein C, Morio T, Oksenhendler E, Puel A, Puck J, Sepp\u00e4nen MRJ, Somech R, Su HC, Sullivan KE, Torgerson TR, Meyts I. The 2022 update of IUIS phenotypical classification for human inborn errors of immunity. J Clin Immunol. 2022;42(7):1508\u201320.","journal-title":"J Clin Immunol"},{"issue":"1","key":"830_CR8","doi-asserted-by":"publisher","first-page":"e20250002","DOI":"10.70962\/jhi.20250002","volume":"1","author":"AA Ahmed Aziz Bousfiha","year":"2025","unstructured":"Ahmed Aziz Bousfiha AA, Jeddane L, Moundir A, Poli MC, Aksentijevich I, Cunningham-Rundles C, Hambleton S, Klein C, Morio T, Picard C, Puel A, Rezaei N, Sepp\u00e4nen MRJ, Somech R, Su HC, Sullivan KE, Torgerson TR, Tangye SG, Meyts I. The 2024 update of IUIS phenotypic classification of human inborn errors of immunity. J Hum Immun. 2025;1(1):e20250002.","journal-title":"J Hum Immun"},{"issue":"1","key":"830_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10875-023-01633-1","volume":"44","author":"AZ Banday","year":"2023","unstructured":"Banday AZ, Nisar R, Patra PK, Kaur A, Sadanand R, Chaudhry C, et al. Clinical and immunological features, genetic variants, and outcomes of patients with CD40 deficiency. J Clin Immunol. 2023;44(1):17.","journal-title":"J Clin Immunol"},{"issue":"3","key":"830_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/j.1365-2249.2007.03432.x","volume":"149","author":"P Wood","year":"2007","unstructured":"Wood P, Stanworth S, Burton J, Jones A, Peckham DG, Green T, et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol. 2007;149(3):410\u201323.","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"830_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.alit.2021.07.007","volume":"70","author":"Y Minegishi","year":"2021","unstructured":"Minegishi Y. Hyper-IgE syndrome, 2021 update. Allergol Int. 2021;70(4):407\u201314.","journal-title":"Allergol Int"},{"issue":"8","key":"830_CR12","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1080\/1744666X.2021.1925543","volume":"17","author":"N Sharifinejad","year":"2021","unstructured":"Sharifinejad N, Zaki-Dizaji M, Tebyanian S, Zainaldain H, Jamee M, Rizvi FS, et al. Clinical, immunological, and genetic features in 938 patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a systematic review. Expert Rev Clin Immunol. 2021;17(8):807\u201317.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"830_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s12016-020-08800-x","volume":"61","author":"HH Yu","year":"2021","unstructured":"Yu HH, Yang YH, Chiang BL. Chronic granulomatous disease: a comprehensive review. Clin Rev Allergy Immunol. 2021;61(2):101\u201313.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"830_CR14","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1182\/blood-2013-07-515528","volume":"123","author":"MA Spinner","year":"2014","unstructured":"Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, Arthur DC, Gu W, Gould CM, Brewer CC, Cowen EW, Freeman AF, Olivier KN, Uzel G, Zelazny AM, Daub JR, Spalding CD, Claypool RJ, Giri NK, Alter BP, Mace EM, Orange JS, Cuellar-Rodriguez J, Hickstein DD, Holland SM. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood. 2014;123(6):809\u201321.","journal-title":"Blood"},{"key":"830_CR15","doi-asserted-by":"publisher","first-page":"1051673","DOI":"10.3389\/fimmu.2022.1051673","volume":"13","author":"Y Qiu","year":"2022","unstructured":"Qiu Y, Fang G, Ye F, Zeng W, Tang M, Wei X, et al. Pathogen spectrum and immunotherapy in patients with anti-IFN-\u03b3 autoantibodies: a multicenter retrospective study and systematic review. Front Immunol. 2022;13:1051673.","journal-title":"Front Immunol"},{"issue":"6","key":"830_CR16","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/ACI.0000000000001039","volume":"24","author":"P Olbrich","year":"2024","unstructured":"Olbrich P, Freeman AF. STAT1 and STAT3 gain of function: clinically heterogenous immune regulatory disorders. Curr Opin Allergy Clin Immunol. 2024;24(6):440\u20137.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"10","key":"830_CR17","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/cid\/ciu646","volume":"59","author":"C Aguilar","year":"2014","unstructured":"Aguilar C, Malphettes M, Donadieu J, Chandesris O, Coignard-Biehler H, Catherinot E, et al. Prevention of infections during primary immunodeficiency. Clin Infect Dis. 2014;59(10):1462\u201370.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"830_CR18","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.jped.2020.10.005","volume":"97","author":"GRS Segundo","year":"2021","unstructured":"Segundo GRS, Condino-Neto A. Treatment of patients with immunodeficiency: medication, gene therapy, and transplantation. J Pediatr (Rio J). 2021;97(Suppl 1):S17-23.","journal-title":"J Pediatr (Rio J)"},{"issue":"Suppl 1","key":"830_CR19","doi-asserted-by":"publisher","first-page":"S283","DOI":"10.1093\/infdis\/jiu295","volume":"210","author":"CC Burns","year":"2014","unstructured":"Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis. 2014;210(Suppl 1):S283-93.","journal-title":"J Infect Dis"},{"key":"830_CR20","unstructured":"Vaccine-derived polioviruses detected worldwide, July 2012\u2013December 2013. Wkly Epidemiol Rec. 2014;89:117\u201327."},{"key":"830_CR21","volume-title":"Vaccines","author":"CF Estivariz","year":"2023","unstructured":"Estivariz CF, Burns CC, Macklin GR. Poliovirus Vaccine\u2014Live. In: Orenstein WA, Offit PA, Edwards KM, Plotkin S.A., editors. Vaccines. 8th ed. Philadelphia, PA, USA: Elsevier; 2023.","edition":"8"},{"key":"830_CR22","doi-asserted-by":"publisher","first-page":"909","DOI":"10.15585\/mmwr.mm7341a1","volume":"73","author":"A Namageyo-Funa","year":"2024","unstructured":"Namageyo-Funa A, Greene SA, Henderson E, Traor\u00e9 MA, Shaukat S, Bigouette JP, et al. Update on vaccine-derived poliovirus outbreaks - worldwide, january 2023-june 2024. MMWR Morb Mortal Wkly Rep. 2024;73:909\u201316.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"830_CR23","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0140-6736(22)01804-9","volume":"400","author":"D Klapsa","year":"2022","unstructured":"Klapsa D, Wilton T, Zealand A, Bujaki E, Saxentoff E, Troman C, et al. Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance. Lancet. 2022;400:1531\u20138.","journal-title":"Lancet"},{"key":"830_CR24","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.15585\/mmwr.mm7133e2","volume":"71","author":"R Link-Gelles","year":"2022","unstructured":"Link-Gelles R, Lutterloh E, Schnabel Ruppert P, Backenson PB, St George K, Rosenberg ES, et al. Public health response to a case of paralytic poliomyelitis in an unvaccinated person and detection of poliovirus in wastewater - New York, June-August 2022. MMWR Morb Mortal Wkly Rep. 2022;71:1065\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"830_CR25","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1017\/S0950268823001127","volume":"151","author":"B Kasstan","year":"2023","unstructured":"Kasstan B, Mounier-Jack S, Chantler T, Masters N, Flores SA, Stokley S, Meek H, Easton D, De Luna-Evans T, Souto M, Punjabi C, Ruppert PS, Rosenberg E, Routh J. Poliovirus outbreak in new York State, August 2022: qualitative assessment of immediate public health responses and priorities for improving vaccine coverage. Epidemiol Infect. 2023;151:e120.","journal-title":"Epidemiol Infect"},{"issue":"3","key":"830_CR26","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2025.30.3.2500037","volume":"30","author":"S B\u00f6ttcher","year":"2025","unstructured":"B\u00f6ttcher S, Kreibich J, Wilton T, Saliba V, Blomqvist S, Al-Hello H, et al. Detection of circulating vaccine-derived poliovirus type 2 (cVDPV2) in wastewater samples: a wake-up call, Finland, Germany, Poland, Spain, the United Kingdom, 2024. Euro Surveill. 2025;30(3):2500037.","journal-title":"Euro Surveill"},{"key":"830_CR27","unstructured":"Pakistan polio eradication programme. In: Polio vaccination and international travel. https:\/\/www.endpolio.com.pk\/certificate\/vaccination-certificate Accessed: 8 April 2025."},{"key":"830_CR28","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3390\/pathogens13121128","volume":"13","author":"CF Estivariz","year":"2024","unstructured":"Estivariz CF, Krow-Lucal ER, Mach O. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) infections: a review of epidemiology and progress in detection and management. Pathogens. 2024;13:1128.","journal-title":"Pathogens"},{"key":"830_CR29","doi-asserted-by":"publisher","first-page":"913","DOI":"10.15585\/mmwr.mm6928a4","volume":"69","author":"G Macklin","year":"2020","unstructured":"Macklin G, Diop OM, Humayun A, Shahmahmoodi S, El-Sayed ZA, Triki H, et al. Update on immunodeficiency-associated vaccine-derived polioviruses - worldwide, july 2018-december 2019. MMWR Morb Mortal Wkly Rep. 2020;69:913\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"830_CR30","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.vaccine.2018.02.059","volume":"36","author":"M Shaghaghi","year":"2018","unstructured":"Shaghaghi M, Soleyman-Jahi S, Abolhassani H, Yazdani R, Azizi G, Rezaei N, et al. New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data. Vaccine. 2018;36:1711\u20139.","journal-title":"Vaccine"},{"key":"830_CR31","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1038\/s41467-023-39094-0","volume":"14","author":"A Singanayagam","year":"2023","unstructured":"Singanayagam A, Klapsa D, Burton-Fanning S, Hand J, Wilton T, Stephens L, Mate R, Shillitoe B, Celma C, Slatter M, Flood T, Gopal R, Martin J, Zambon M. Asymptomatic immunodeficiency-associated vaccine-derived poliovirus infections in two UK children. Nat Commun. 2023;14:3413.","journal-title":"Nat Commun"},{"key":"830_CR32","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s10875-018-0521-z","volume":"38","author":"M Shaghaghi","year":"2018","unstructured":"Shaghaghi M, Irannejad M, Abolhassani H, Shahmahmoodi S, Hamidieh AA, Soleyman-Jahi S, et al. Clearing vaccine-derived poliovirus infection following hematopoietic stem cell transplantation: a case report and review of literature. J Clin Immunol. 2018;38:610\u20136.","journal-title":"J Clin Immunol"},{"key":"830_CR33","doi-asserted-by":"publisher","first-page":"1135834","DOI":"10.3389\/fimmu.2023.1135834","volume":"14","author":"WH Bermingham","year":"2023","unstructured":"Bermingham WH, Canning B, Wilton T, Kidd M, Klapsa D, Majumdar M, Sooriyakumar K, Martin J, Huissoon AP. Case report: clearance of longstanding, immune-deficiency-associated, vaccine-derived polio virus infection following Remdesivir therapy for chronic SARS-CoV-2 infection. Front Immunol. 2023;14:1135834.","journal-title":"Front Immunol"},{"key":"830_CR34","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/INF.0000000000002584","volume":"39","author":"J Copelyn","year":"2020","unstructured":"Copelyn J, Hincks JR, Wilmshurst JM, Petersen W, Howard W, Jallow S, et al. Clearance of immunodeficiency-associated vaccine-derived poliovirus infection with Pocapavir. Pediatr Infect Dis J. 2020;39:435\u20137.","journal-title":"Pediatr Infect Dis J"},{"key":"830_CR35","first-page":"335","volume":"215","author":"MS Collett","year":"2017","unstructured":"Collett MS, Hincks JR, Benschop K, Duizer E, van der Avoort H, Rhoden E, Liu H, Oberste MS, McKinlay MA, Hartford M. Antiviral activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled human oral poliovirus vaccine challenge model. J Infect Dis. 2017;215:335\u201343.","journal-title":"J Infect Dis"},{"key":"830_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1053\/jinf.2002.1066","volume":"46","author":"E Halliday","year":"2003","unstructured":"Halliday E, Winkelstein J, Webster AD. Enteroviral infections in primary immunodeficiency (PID): a survey of morbidity and mortality. J Infect. 2003;46:1\u20138.","journal-title":"J Infect"},{"key":"830_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2019.100018","volume":"12","author":"ZA El-Sayed","year":"2019","unstructured":"El-Sayed ZA, Abramova I, Aldave JC, Al-Herz W, Bezrodnik L, Boukari R, et al. X-linked agammaglobulinemia (XLA): phenotype, diagnosis, and therapeutic challenges around the world. World Allergy Organ J. 2019;12:100018.","journal-title":"World Allergy Organ J"},{"key":"830_CR38","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/01.md.0000229482.27398.ad","volume":"85","author":"JA Winkelstein","year":"2006","unstructured":"Winkelstein JA, Marino MC, Lederman HM, Jones SM, Sullivan K, Burks AW, et al. X-linked agammaglobulinemia: report on a united States registry of 201 patients. Medicine (Baltimore). 2006;85:193\u2013202.","journal-title":"Medicine (Baltimore)"},{"key":"830_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12879-018-2946-7","volume":"18","author":"DW Lewandowska","year":"2018","unstructured":"Lewandowska DW, Capaul R, Prader S, Zagordi O, Geissberger FD, K\u00fcgler M, Knorr M, Berger C, G\u00fcng\u00f6r T, Reichenbach J, Shah C, B\u00f6ni J, Zbinden A, Trkola A, Pachlopnik Schmid J, Huber M. Persistent mammalian orthoreovirus, coxsackievirus and adenovirus co-infection in a child with a primary immunodeficiency detected by metagenomic sequencing: a case report. BMC Infect Dis. 2018;18:33.","journal-title":"BMC Infect Dis"},{"key":"830_CR40","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1128\/JCM.01122-14","volume":"52","author":"N Driss","year":"2014","unstructured":"Driss N, Mellouli F, Ben Yahia A, Touzi H, Barbouche MR, Triki H, Bejaoui M. Sequential asymptomatic enterovirus infections in a patient with major histocompatibility complex class II primary immunodeficiency. J Clin Microbiol. 2014;52:3486\u20139.","journal-title":"J Clin Microbiol"},{"key":"830_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijid.2021.10.002","volume":"113","author":"JN Wagner","year":"2021","unstructured":"Wagner JN, Leibetseder A, Troescher A, Panholzer J, von Oertzen TJ. Characteristics and therapy of enteroviral encephalitis: case report and systematic literature review. Int J Infect Dis. 2021;113:93\u2013102.","journal-title":"Int J Infect Dis"},{"key":"830_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106142","volume":"88","author":"A Meinhardt","year":"2024","unstructured":"Meinhardt A, Reilly L, Kaliakatsos M, Abdel-Aziz K, Alsharidah S, Bodi I, et al. Novel antivirals for severe enterovirus infection in immunocompromised hosts; a case series. J Infect. 2024;88:106142.","journal-title":"J Infect"},{"key":"830_CR43","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10875-024-01740-7","volume":"44","author":"L Yu","year":"2024","unstructured":"Yu L, Zhang Y, Li W, Mao J, Li Y, Wang H, Li C, Yang L, He W, Jia Y, Tang W, Zhou L, Zhang Z, Jia Y, Tang X, Zhao X, An Y. Fluoxetine successfully treats intracranial enterovirus E18 infection in a patient with CD79a deficiency arising from segmental uniparental disomy of chromosome 19. J Clin Immunol. 2024;44:137.","journal-title":"J Clin Immunol"},{"key":"830_CR44","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pediatrneurol.2016.06.014","volume":"64","author":"J Gofshteyn","year":"2016","unstructured":"Gofshteyn J, C\u00e1rdenas AM, Bearden D. Treatment of chronic enterovirus encephalitis with fluoxetine in a patient with X-linked agammaglobulinemia. Pediatr Neurol. 2016;64:94\u20138.","journal-title":"Pediatr Neurol"},{"key":"830_CR45","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/jamaneurol.2014.4625","volume":"72","author":"KL Tyler","year":"2015","unstructured":"Tyler KL. Rationale for the evaluation of Fluoxetine in the treatment of enterovirus D68-associated acute flaccid myelitis. JAMA Neurol. 2015;72:493\u20134.","journal-title":"JAMA Neurol"},{"key":"830_CR46","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1128\/AAC.43.9.2109","volume":"43","author":"DC Pevear","year":"1999","unstructured":"Pevear DC, Tull TM, Seipel ME, Groarke JM. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother. 1999;43:2109\u201315.","journal-title":"Antimicrob Agents Chemother"},{"key":"830_CR47","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/jpids\/piv015","volume":"5","author":"MJ Abzug","year":"2016","unstructured":"Abzug MJ, Michaels MG, Wald E, Jacobs RF, Romero JR, S\u00e1nchez PJ, et al. A randomized, double-blind, placebo-controlled trial of pleconaril for the treatment of neonates with enterovirus sepsis. J Pediatr Infect Dis Soc. 2016;5:53\u201362.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"830_CR48","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s00508-017-1289-5","volume":"130","author":"I Radanovi\u0107","year":"2018","unstructured":"Radanovi\u0107 I, Rkman D, Zekan P, Kutle\u0161a M, Bar\u0161i\u0107 B. Chronic meningoencephalitis caused by echo virus 6 in a patient with common variable immunodeficiency: successful treatment with pleconaril. Wien Klin Wochenschr. 2018;130:70\u20132.","journal-title":"Wien Klin Wochenschr"},{"key":"830_CR49","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3851\/IMP1936","volume":"17","author":"JG Wildenbeest","year":"2012","unstructured":"Wildenbeest JG, van den Broek PJ, Benschop KS, Koen G, Wierenga PC, Vossen AC, et al. Pleconaril revisited: clinical course of chronic enteroviral meningoencephalitis after treatment correlates with in vitro susceptibility. Antivir Ther. 2012;17:459\u201366.","journal-title":"Antivir Ther"},{"key":"830_CR50","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s13365-021-01038-z","volume":"28","author":"S Epstein","year":"2022","unstructured":"Epstein S, Thakkar R, Fong KT, Ng J, Bearden DR, Mishra N, et al. Compassionate-use Pocapavir and immunoglobulin therapy for treatment of rituximab-associated enterovirus meningoencephalitis. J Neurovirol. 2022;28:329\u201334.","journal-title":"J Neurovirol"},{"key":"830_CR51","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","volume":"93","author":"Y Furuta","year":"2017","unstructured":"Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93:449\u201363.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"830_CR52","doi-asserted-by":"publisher","first-page":"930031","DOI":"10.3389\/fimmu.2022.930031","volume":"13","author":"K Chetty","year":"2022","unstructured":"Chetty K, Cheng I, Kaliakatsos M, Gonzalez-Granado LI, Klapsa D, Martin J, Bamford A, Breuer J, Booth C. Case report: novel treatment regimen for enterovirus encephalitis in SCID. Front Immunol. 2022;13:930031.","journal-title":"Front Immunol"},{"key":"830_CR53","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","volume":"110","author":"JF Rossignol","year":"2014","unstructured":"Rossignol JF. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res. 2014;110:94\u2013103.","journal-title":"Antiviral Res"},{"key":"830_CR54","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s40262-020-00871-5","volume":"59","author":"V Al Jalali","year":"2020","unstructured":"Al Jalali V, Zeitlinger M. Systemic and target-site pharmacokinetics of antiparasitic agents. Clin Pharmacokinet. 2020;59:827\u201347.","journal-title":"Clin Pharmacokinet"},{"key":"830_CR55","doi-asserted-by":"publisher","first-page":"27148","DOI":"10.1038\/srep27148","volume":"6","author":"D Trabattoni","year":"2016","unstructured":"Trabattoni D, Gnudi F, Ibba SV, Saulle I, Agostini S, Masetti M, et al. Thiazolides elicit anti-viral innate immunity and reduce HIV replication. Sci Rep. 2016;6:27148.","journal-title":"Sci Rep"},{"key":"830_CR56","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s10875-018-0534-7","volume":"38","author":"J Leung","year":"2018","unstructured":"Leung J, Sullivan KE, Perelygina L, Icenogle JP, Fuleihan RL, Lanzieri TM. Prevalence of granulomas in patients with primary immunodeficiency disorders, United states: data from National health care claims and the US immunodeficiency network registry. J Clin Immunol. 2018;38:717\u201326.","journal-title":"J Clin Immunol"},{"key":"830_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12573","volume":"20","author":"C Bodemer","year":"2014","unstructured":"Bodemer C, Sauvage V, Mahlaoui N, Cheval J, Couderc T, Leclerc-Mercier S, et al. Live rubella virus vaccine long-term persistence as an antigenic trigger of cutaneous granulomas in patients with primary immunodeficiency. Clin Microbiol Infect. 2014;20:O656\u201363.","journal-title":"Clin Microbiol Infect"},{"key":"830_CR58","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/ACI.0000000000000694","volume":"20","author":"L Perelygina","year":"2020","unstructured":"Perelygina L, Icenogle J, Sullivan KE. Rubella virus-associated chronic inflammation in primary immunodeficiency diseases. Curr Opin Allergy Clin Immunol. 2020;20:574\u201381.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"830_CR59","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jaad.2023.05.058","volume":"90","author":"D Zhang","year":"2024","unstructured":"Zhang D, Wanat KA, Perelygina L, Rosenbach M, Haun PL, Drolet BA, et al. Cutaneous granulomas associated with Rubella virus: a clinical review. J Am Acad Dermatol. 2024;90:111\u201321.","journal-title":"J Am Acad Dermatol"},{"key":"830_CR60","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10875-018-0581-0","volume":"39","author":"D Buchbinder","year":"2019","unstructured":"Buchbinder D, Hauck F, Albert MH, Rack A, Bakhtiar S, Shcherbina A, et al. Rubella virus associated cutaneous granulomatous disease: a unique complication in immune-deficient patients, not limited to DNA repair disorders. J Clin Immunol. 2019;39:81\u20139.","journal-title":"J Clin Immunol"},{"key":"830_CR61","doi-asserted-by":"publisher","first-page":"1075351","DOI":"10.3389\/fimmu.2022.1075351","volume":"13","author":"KE Bonner","year":"2022","unstructured":"Bonner KE, Sukerman E, Liko J, Lanzieri TM, Sutton M, DeBess E, Leesman C, Icenogle J, Hao L, Chen MH, Faisthalab R, Leman RF, Cieslak PR, DeRavinSS, Perelygina L. Case report: persistent shedding of a live vaccine-derived Rubella virus in a young man with severe combined immunodeficiency and cutaneous granuloma. Front Immunol. 2022;13:1075351.","journal-title":"Front Immunol"},{"key":"830_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.796065","volume":"12","author":"L Perelygina","year":"2021","unstructured":"Perelygina L, Faisthalab R, Abernathy E, Chen MH, Hao L, Bercovitch L, et al. Rubella virus infected macrophages and neutrophils define patterns of granulomatous inflammation in inborn and acquired errors of immunity. Front Immunol. 2021;12:796065.","journal-title":"Front Immunol"},{"key":"830_CR63","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jaci.2021.05.007","volume":"149","author":"M Gross","year":"2022","unstructured":"Gross M, Speckmann C, May A, Gajardo-Carrasco T, Wustrau K, Maier SL, Panning M, Huzly D, Agaimy A, Bryceson YT, Choo S, Chow CW, D\u00fcckers G, Fasth A, Fraitag S, Gr\u00e4we K, Haxelmans S, Holzinger D, Hudowenz O, H\u00fcbschen JM, Khurana C, Kienle K, Klifa R, Korn K, Kutzner H, L\u00e4mmermann T, Ledig S, Lipsker D, Meeths M, Naumann-Bartsch N, Rascon J, Sch\u00e4nzer A, Seidl M, Tesi B, Vauloup-Fellous C, Vollmer-Kary B, Warnatz K, Wehr C, Neven B, Vargas P, Sepulveda FE, Lehmberg K, Schmitt-Graeff A, Ehl S. Rubella vaccine-induced granulomas are a novel phenotype with incomplete penetrance of genetic defects in cytotoxicity. J Allergy Clin Immunol. 2022;149:388\u2013e3994.","journal-title":"J Allergy Clin Immunol"},{"key":"830_CR64","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1001\/jamadermatol.2022.0828","volume":"158","author":"KA Wanat","year":"2022","unstructured":"Wanat KA, Perelygina L, Chen MH, Hao L, Abernathy E, Bender NR, et al. Association of persistent Rubella virus with idiopathic skin granulomas in clinically immunocompetent adults. JAMA Dermatol. 2022;158:626\u201333.","journal-title":"JAMA Dermatol"},{"key":"830_CR65","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1001\/jamadermatol.2021.1577","volume":"157","author":"BE Shields","year":"2021","unstructured":"Shields BE, Perelygina L, Samimi S, Haun P, Leung T, Abernathy E, et al. Granulomatous dermatitis associated with Rubella virus infection in an adult with immunodeficiency. JAMA Dermatol. 2021;157:842\u20137.","journal-title":"JAMA Dermatol"},{"key":"830_CR66","first-page":"e938","volume":"230","author":"MH Chen","year":"2024","unstructured":"Chen MH, Perelygina L, Hao L, Beard RS, Lackner C, Farcet MR, et al. Neutralization of Rubella vaccine virus and Immunodeficiency-related vaccine-derived Rubella viruses by intravenous Immunoglobulins. J Infect Dis. 2024;230:e938-42.","journal-title":"J Infect Dis"},{"key":"830_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008080","volume":"15","author":"L Perelygina","year":"2019","unstructured":"Perelygina L, Chen MH, Suppiah S, Adebayo A, Abernathy E, Dorsey M, et al. Infectious vaccine-derived Rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies. PLoS Pathog. 2019;15:e1008080.","journal-title":"PLoS Pathog"},{"key":"830_CR68","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.antiviral.2017.09.019","volume":"147","author":"L Perelygina","year":"2017","unstructured":"Perelygina L, Hautala T, Sepp\u00e4nen M, Adebayo A, Sullivan KE, Icenogle J. Inhibition of Rubella virus replication by the broad-spectrum drug Nitazoxanide in cell culture and in a patient with a primary immune deficiency. Antivir Res. 2017;147:58\u201366.","journal-title":"Antivir Res"},{"key":"830_CR69","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3390\/pathogens11030338","volume":"11","author":"R Faisthalab","year":"2022","unstructured":"Faisthalab R, Suppiah S, Dorsey M, Sullivan KE, Icenogle J, Perelygina L. Drug sensitivity of vaccine-derived rubella viruses and quasispecies evolution in granulomatous lesions of two Ataxia-telangiectasia patients treated with Nitazoxanide. Pathogens. 2022;11:338.","journal-title":"Pathogens"},{"key":"830_CR70","doi-asserted-by":"publisher","first-page":"1483149","DOI":"10.3389\/fpubh.2024.1483149","volume":"12","author":"M Zhu","year":"2025","unstructured":"Zhu M, Huang Z, Liu T, Wu C, Shang Z, Zhang L. Global burden and trends of norovirus-associated diseases from 1990 to 2021 an observational trend study. Front Public Health. 2025;12:1483149.","journal-title":"Front Public Health"},{"key":"830_CR71","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nrmicro.2016.48","volume":"14","author":"M de Graaf","year":"2016","unstructured":"de Graaf M, van Beek J, Koopmans MP. Human Norovirus transmission and evolution in a changing world. Nat Rev Microbiol. 2016;14:421\u201333.","journal-title":"Nat Rev Microbiol"},{"key":"830_CR72","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw169","volume":"3","author":"K Bok","year":"2016","unstructured":"Bok K, Prevots DR, Binder AM, Parra GI, Strollo S, Fahle GA, et al. Epidemiology of Norovirus infection among immunocompromised patients at a tertiary care research hospital, 2010\u20132013. Open Forum Infect Dis. 2016;3:ofw169.","journal-title":"Open Forum Infect Dis"},{"key":"830_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.1926","volume":"27","author":"LK Brown","year":"2017","unstructured":"Brown LK, Clark I, Brown JR, Breuer J, Lowe DM. Norovirus infection in primary immune deficiency. Rev Med Virol. 2017;27:e1926.","journal-title":"Rev Med Virol"},{"key":"830_CR74","doi-asserted-by":"crossref","unstructured":"Chaimongkol N, Kim DY, Matsushima Y, Durkee-Shock J, Barton K, Ahorrio CN, Fahle GA, Bok K, Behrle-Yardley A, Johnson JA, de Jes\u00fas-D\u00edaz DA, Parra GI, Levenson EA, Maeda FY, Sosnovtsev SV, Green KY. A decade of chronic Norovirus infection surveillance at the NIH clinical research center: clinical Characteristics, molecular Epidemiology, and replication. J Infect Dis. 2024:jiae440.","DOI":"10.1093\/infdis\/jiae440"},{"key":"830_CR75","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2018.08.002","volume":"93","author":"MC Rolfes","year":"2019","unstructured":"Rolfes MC, Sriaroon P, D\u00e1vila Salda\u00f1a BJ, Dvorak CC, Chapdelaine H, Ferdman RM, et al. Chronic norovirus infection in primary immune deficiency disorders: an international case series. Diagn Microbiol Infect Dis. 2019;93:69\u201373.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"830_CR76","doi-asserted-by":"crossref","unstructured":"Grammatikos A, Mangtani A, Ponsford M, Jolles S, McDermott E, Johnston S, Frleta-Gilchrist M, Yong P, Moghaddas F, Thomas M, Patel S, Blundell C, Bright P, Drewe E, Elcombe S, Herwadkar A, Murng S, Kim DI, Gompels M, Lowe D. Chronic Norovirus infection in immunodeficiency: A UK National case series. J Allergy Clin Immunol Pract. 2025;S2213-2198:00198-9.","DOI":"10.1016\/j.jaip.2025.02.026"},{"key":"830_CR77","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1182\/blood-2007-11-124545","volume":"112","author":"H Chapel","year":"2008","unstructured":"Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, Fieschi C, Thon V, Abedi MR, Hammarstrom L. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112:277\u201386.","journal-title":"Blood"},{"key":"830_CR78","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/ajg.2014.432","volume":"110","author":"JM Woodward","year":"2015","unstructured":"Woodward JM, Gkrania-Klotsas E, Cordero-Ng AY, Aravinthan A, Bandoh BN, Liu H, et al. The role of chronic norovirus infection in the enteropathy associated with common variable immunodeficiency. Am J Gastroenterol. 2015;110:320\u20137.","journal-title":"Am J Gastroenterol"},{"key":"830_CR79","doi-asserted-by":"publisher","first-page":"648","DOI":"10.14309\/ajg.0000000000000140","volume":"114","author":"S Pikkarainen","year":"2019","unstructured":"Pikkarainen S, Martelius T, Ristim\u00e4ki A, Siitonen S, Sepp\u00e4nen MRJ, F\u00e4rkkil\u00e4 M. A high prevalence of gastrointestinal manifestations in common variable immunodeficiency. Am J Gastroenterol. 2019;114:648\u201355.","journal-title":"Am J Gastroenterol"},{"key":"830_CR80","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.jaci.2019.07.036","volume":"144","author":"LK Brown","year":"2019","unstructured":"Brown LK, Ruis C, Clark I, Roy S, Brown JR, Albuquerque AS, et al. A comprehensive characterization of chronic norovirus infection in immunodeficient hosts. J Allergy Clin Immunol. 2019;144:1450\u20133.","journal-title":"J Allergy Clin Immunol"},{"key":"830_CR81","doi-asserted-by":"publisher","first-page":"e0217723","DOI":"10.1128\/mbio.02177-23","volume":"14","author":"N Chaimongkol","year":"2023","unstructured":"Chaimongkol N, D\u00e1billa N, Tohma K, Matsushima Y, Yardley AB, Levenson EA, Johnson JA, Ahorrio C, Oler AJ, Kim DY, Souza M, Sosnovtsev SV, Parra GI, Green KY. Norovirus evolves as one or more distinct clonal populations in immunocompromised hosts. mBio. 2023;14:e0217723.","journal-title":"mBio"},{"key":"830_CR82","doi-asserted-by":"publisher","first-page":"105391","DOI":"10.1016\/j.ebiom.2024.105391","volume":"109","author":"RW Izquierdo-Lara","year":"2024","unstructured":"Izquierdo-Lara RW, Villabruna N, Hesselink DA, Schapendonk CME, Rib\u00f3 Pons S, Nieuwenhuijse D, et al. Patterns of the within-host evolution of human norovirus in immunocompromised individuals and implications for treatment. EBioMedicine. 2024;109:105391.","journal-title":"EBioMedicine"},{"key":"830_CR83","doi-asserted-by":"publisher","first-page":"100401","DOI":"10.1016\/j.epidem.2020.100401","volume":"32","author":"PFM Teunis","year":"2020","unstructured":"Teunis PFM, Le Guyader FS, Liu P, Ollivier J, Moe CL. Noroviruses are highly infectious but there is strong variation in host susceptibility and virus pathogenicity. Epidemics. 2020;32:100401.","journal-title":"Epidemics"},{"key":"830_CR84","doi-asserted-by":"publisher","first-page":"4303","DOI":"10.1128\/JCM.01308-10","volume":"48","author":"FH Sukhrie","year":"2010","unstructured":"Sukhrie FH, Siebenga JJ, Beersma MF, Koopmans M. Chronic shedders as reservoir for nosocomial transmission of norovirus. J Clin Microbiol. 2010;48:4303\u20135.","journal-title":"J Clin Microbiol"},{"key":"830_CR85","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/cid\/cit287","volume":"57","author":"S Kundu","year":"2013","unstructured":"Kundu S, Lockwood J, Depledge DP, Chaudhry Y, Aston A, Rao K, Hartley JC, Goodfellow I, Breuer J. Next-generation whole genome sequencing identifies the direction of Norovirus transmission in linked patients. Clin Infect Dis. 2013;57:407\u201314.","journal-title":"Clin Infect Dis"},{"key":"830_CR86","doi-asserted-by":"publisher","first-page":"e03679","DOI":"10.7554\/eLife.03679","volume":"3","author":"A Arias","year":"2014","unstructured":"Arias A, Thorne L, Goodfellow I. Favipiravir elicits antiviral mutagenesis during virus replication in vivo. Elife. 2014;3:e03679.","journal-title":"Elife"},{"key":"830_CR87","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1056\/NEJMc1806941","volume":"379","author":"C Ruis","year":"2018","unstructured":"Ruis C, Brown LK, Roy S, Atkinson C, Williams R, Burns SO, Yara-Romero E, Jacobs M, Goldstein R, Breuer J, Lowe DM. Mutagenesis in Norovirus in response to favipiravir treatment. N Engl J Med. 2018;379:2173\u20136.","journal-title":"N Engl J Med"},{"key":"830_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.109901","volume":"259","author":"AY Kreins","year":"2024","unstructured":"Kreins AY, Roux E, Pang J, Cheng I, Charles O, Roy S, et al. Favipiravir induces HuNoV viral mutagenesis and infectivity loss with clinical improvement in immunocompromised patients. Clin Immunol. 2024;259:109901.","journal-title":"Clin Immunol"},{"key":"830_CR89","doi-asserted-by":"publisher","first-page":"7174","DOI":"10.3748\/wjg.v23.i39.7174","volume":"23","author":"P Lahtinen","year":"2017","unstructured":"Lahtinen P, Mattila E, Anttila VJ, Tillonen J, Teittinen M, Nevalainen P, et al. Faecal microbiota transplantation in patients with clostridium difficile and significant comorbidities as well as in patients with new indications: a case series. World J Gastroenterol. 2017;23:7174\u201384.","journal-title":"World J Gastroenterol"},{"key":"830_CR90","doi-asserted-by":"crossref","unstructured":"Durkee-Shock J, Cohen A, Maghzian N, Pezzella G, Jensen-Wachspress M, Hostal A, Barton K, Gangler K, D\u00e1vila Salda\u00f1a BJ, Chaimongkol N, Bollard CM, Sosnovtsev SV, Cohen J, Nagata BM, Alves DA, Ghosh R, Seifert BA, Freeman A, Gonzalez C, Notarangelo LD, Green KY, Keller MD. Reconstitution of Norovirus-specific T cell responses following hematopoietic stem cell transplantation in patients with inborn errors of immunity and chronic Norovirus infection. J Infect Dis. 2024:jiae398.","DOI":"10.1016\/j.clim.2024.110015"},{"issue":"5","key":"830_CR91","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1399-3046.2011.01500.x","volume":"15","author":"MA Saif","year":"2011","unstructured":"Saif MA, Bonney DK, Bigger B, Forsythe L, Williams N, Page J, et al. Chronic norovirus infection in pediatric hematopoietic stem cell transplant recipients: a cause of prolonged intestinal failure requiring intensive nutritional support. Pediatr Transplant. 2011;15(5):505\u20139.","journal-title":"Pediatr Transplant"},{"key":"830_CR92","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","volume":"17","author":"I Cortese","year":"2021","unstructured":"Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol. 2021;17:37\u201351.","journal-title":"Nat Rev Neurol"},{"key":"830_CR93","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10875-018-0578-8","volume":"39","author":"J Hadjadj","year":"2019","unstructured":"Hadjadj J, Guffroy A, Delavaud C, Taieb G, Meyts I, Fresard A, Streichenberger N, L\u2019Honneur AS, Rozenberg F, D\u2019Aveni M, Aguilar C, Rosain J, Picard C, Mahlaoui N, Lecuit M, Hermine O, Lortholary O, Suarez F. Progressive multifocal leukoencephalopathy in primary immunodeficiencies. J Clin Immunol. 2019;39:55\u201364.","journal-title":"J Clin Immunol"},{"key":"830_CR94","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1093\/cid\/civ1220","volume":"62","author":"CS Zerbe","year":"2016","unstructured":"Zerbe CS, Marciano BE, Katial RK, Santos CB, Adamo N, Hsu AP, Hanks ME, Darnell DN, Quezado MM, Frein C, Barnhart LA, Anderson VL, Uzel G, Freeman AF, Lisco A, Nath A, Major EO, Sampaio EP, Holland SM. Progressive multifocal leukoencephalopathy in primary immune deficiencies: Stat1 gain of function and review of the literature. Clin Infect Dis. 2016;62:986\u201394.","journal-title":"Clin Infect Dis"},{"key":"830_CR95","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s13365-019-00738-x","volume":"25","author":"E Hoang","year":"2019","unstructured":"Hoang E, Bartlett NL, Goyal MS, Schmidt RE, Clifford DB. Progressive multifocal leukoencephalopathy treated with nivolumab. J Neurovirol. 2019;25:284\u20137.","journal-title":"J Neurovirol"},{"key":"830_CR96","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.26512","volume":"93","author":"X Boumaza","year":"2023","unstructured":"Boumaza X, Bonneau B, Roos-Weil D, Pinnetti C, Rauer S, Nitsch L, Del Bello A, Jelcic I, S\u00fchs KW, Gasnault J, Goreci Y, Grauer O, Gnanapavan S, Wicklein R, Lambert N, Perpoint T, Beudel M, Clifford D, Sommet A, Cortese I, Martin-Blondel G. Immunotherapy for PML study Group. Progressive multifocal leukoencephalopathy treated by immune checkpoint inhibitors. Ann Neurol. 2023;93:257\u201370.","journal-title":"Ann Neurol"},{"key":"830_CR97","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1002\/jmv.27804","volume":"94","author":"H Yu","year":"2022","unstructured":"Yu H, Wu H, Kaur RS, Pasham A, Upadhaya SR, Sriwastava R. Single-center experience on progressive multifocal leukoencephalopathy (PML) cases, neuroimaging relevance, and management at West Virginia university (WVU). J Med Virol. 2022;94:4015\u201322.","journal-title":"J Med Virol"},{"key":"830_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.120774","volume":"453","author":"H Otaka","year":"2023","unstructured":"Otaka H, Imai S, Fushimi K. Epidemiology of progressive multifocal leukoencephalopathy in Japan and effectiveness of mefloquine: a retrospective analysis of a nationwide inpatient database. J Neurol Sci. 2023;453:120774.","journal-title":"J Neurol Sci"},{"key":"830_CR99","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev.pathol.1.110304.100209","volume":"1","author":"JL Kutok","year":"2006","unstructured":"Kutok JL, Wang F. Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol. 2006;1:375\u2013404.","journal-title":"Annu Rev Pathol"},{"key":"830_CR100","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1182\/blood-2018-04-842559","volume":"132","author":"Y Natkunam","year":"2018","unstructured":"Natkunam Y, Gratzinger D, Chadburn A, Goodlad JR, Chan JKC, Said J, Jaffe ES, de Jong D. Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal? Blood. 2018;132:1871\u20138.","journal-title":"Blood"},{"key":"830_CR101","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1080\/1744666X.2024.2386427","volume":"20","author":"P Barman","year":"2024","unstructured":"Barman P, Basu S, Goyal T, Sharma S, Siniah S, Tyagi R, Sharma K, Jindal AK, Pilania RK, Vignesh P, Dhaliwal M, Suri D, Rawat A, Singh S. Epstein-Barr virus-driven lymphoproliferation in inborn errors of immunity: a diagnostic and therapeutic challenge. Expert Rev Clin Immunol. 2024;20:1331\u201346.","journal-title":"Expert Rev Clin Immunol"},{"key":"830_CR102","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1080\/10428194.2019.1672056","volume":"61","author":"M Herber","year":"2020","unstructured":"Herber M, Mertz P, Dieudonn\u00e9 Y, Guffroy B, Jung S, Gies V, Korganow AS, Guffroy A. Primary immunodeficiencies and lymphoma: a systematic review of literature. Leuk Lymphoma. 2020;61:274\u201384.","journal-title":"Leuk Lymphoma"},{"key":"830_CR103","doi-asserted-by":"publisher","first-page":"856601","DOI":"10.3389\/fimmu.2022.856601","volume":"13","author":"S Sharma","year":"2022","unstructured":"Sharma S, Pilania RK, Anjani G, Sudhakar M, Arora K, Tyagi R, et al. Lymphoproliferation in inborn errors of immunity: the eye does not see what the mind does not know. Front Immunol. 2022;13:856601.","journal-title":"Front Immunol"},{"key":"830_CR104","doi-asserted-by":"publisher","first-page":"1112513","DOI":"10.3389\/fimmu.2023.1112513","volume":"14","author":"RV Hewavisenti","year":"2023","unstructured":"Hewavisenti RV, Arena J, Ahlenstiel CL, Sasson SC. Human papillomavirus in the setting of immunodeficiency: pathogenesis and the emergence of next-generation therapies to reduce the high associated cancer risk. Front Immunol. 2023;14:1112513.","journal-title":"Front Immunol"},{"key":"830_CR105","doi-asserted-by":"publisher","first-page":"789345","DOI":"10.3389\/fimmu.2021.789345","volume":"12","author":"M Gernert","year":"2021","unstructured":"Gernert M, Kiesel M, Fr\u00f6hlich M, Renner R, Strunz PP, Portegys J, Tony HP, Schmalzing M, Schwaneck EC. High prevalence of genital human papillomavirus infection in patients with primary immunodeficiencies. Front Immunol. 2021;12:789345.","journal-title":"Front Immunol"},{"key":"830_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.101028","volume":"26","author":"S Biglari","year":"2024","unstructured":"Biglari S, Moghaddam AS, Tabatabaiefar MA, Sherkat R, Youssefian L, Saeidian AH, et al. Monogenic etiologies of persistent human papillomavirus infections: a comprehensive systematic review. Genet Med. 2024;26:101028.","journal-title":"Genet Med"},{"key":"830_CR107","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jid.2021.10.029","volume":"142","author":"J Uitto","year":"2022","unstructured":"Uitto J, Saeidian AH, Youssefian L, Saffarian Z, Casanova JL, B\u00e9ziat V, et al. Recalcitrant warts, epidermodysplasia verruciformis, and the tree-man syndrome: phenotypic spectrum of cutaneous human papillomavirus infections at the intersection of genetic variability of viral and human genomes. J Invest Dermatol. 2022;142:1265\u20139.","journal-title":"J Invest Dermatol"},{"key":"830_CR108","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3390\/pathogens11080857","volume":"11","author":"A El Kettani","year":"2022","unstructured":"El Kettani A, Ailal F, El Bakkouri J, Zerouali K, B\u00e9ziat V, Jouanguy E, et al. HPV-related skin phenotypes in patients with inborn errors of immunity. Pathogens. 2022;11:857.","journal-title":"Pathogens"},{"key":"830_CR109","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae369","volume":"11","author":"C Matucci-Cerinic","year":"2024","unstructured":"Matucci-Cerinic C, Herzum A, Ciccarese G, Rosina S, Caorsi R, Gattorno M, et al. Therapeutic role of HPV vaccination on benign HPV-induced epithelial proliferations in immunocompetent and immunocompromised patients: case study and review of the literature. Open Forum Infect Dis. 2024;11:ofae369.","journal-title":"Open Forum Infect Dis"},{"key":"830_CR110","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1056\/NEJMoa1808575","volume":"380","author":"DH McDermott","year":"2019","unstructured":"McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019;380:163\u201370.","journal-title":"N Engl J Med"},{"key":"830_CR111","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1182\/blood.2020007197","volume":"136","author":"DC Dale","year":"2020","unstructured":"Dale DC, Firkin F, Bolyard AA, Kelley M, Makaryan V, Gorelick KJ, Ebrahim T, Garg V, Tang W, Jiang H, Skerlj R, Beaussant Cohen S. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood. 2020;136:2994\u20133003.","journal-title":"Blood"},{"key":"830_CR112","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1056\/NEJMoa2102715","volume":"385","author":"A Lisco","year":"2021","unstructured":"Lisco A, Hsu AP, Dimitrova D, Proctor DM, Mace EM, Ye P, Anderson MV, Hicks SN, Grivas C, Hammoud DA, Manion M, Starrett GJ, Farrel A, Dobbs K, Brownell I, Buck C, Notarangelo LD, Orange JS, Leonard WJ, Orestes MI, Peters AT, Kanakry JA, Segre JA, Kong HH, Sereti I. Treatment of relapsing HPV diseases by restored function of natural killer cells. N Engl J Med. 2021;385:921\u20139.","journal-title":"N Engl J Med"},{"key":"830_CR113","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10875-021-01155-8","volume":"42","author":"A Laberko","year":"2022","unstructured":"Laberko A, Deordieva E, Krivan G, Goda V, Bhar S, Kawahara Y, Rao K, Worth A, McDermott DH, Balashov D, Maschan A, Shcherbina A. Multicenter experience of hematopoietic stem cell transplantation in WHIM syndrome. J Clin Immunol. 2022;42:171\u201382.","journal-title":"J Clin Immunol"},{"issue":"14","key":"830_CR114","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1112513","volume":"7","author":"RV Hewavisenti","year":"2023","unstructured":"Hewavisenti RV, Arena J, Ahlenstiel CL, Sasson SC. Human papillomavirus in the setting of immunodeficiency: pathogenesis and the emergence of next-generation therapies to reduce the high associated cancer risk. Front Immunol. 2023;7(14):1112513.","journal-title":"Front Immunol"},{"key":"830_CR115","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1007\/s10875-022-01278-6","volume":"42","author":"JW Day","year":"2022","unstructured":"Day JW, Elfeky R, Nicholson B, Goodman R, Pearce R, Fox TA, Worth A, Booth C, Veys P, Carpenter B, Hough R, Gaspar HB, Titman P, Ridout D, Workman S, Hernandes F, Sandford K, Laurence A, Campbell M, Burns SO, Morris EC, Retrospective. Landmark analysis of Long-term adult morbidity following allogeneic HSCT for inborn errors of immunity in infancy and childhood. J Clin Immunol. 2022;42:1230\u201343.","journal-title":"J Clin Immunol"},{"issue":"Suppl 66","key":"830_CR116","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1046\/j.0366-077X.2003.05627.x","volume":"149","author":"T Schmook","year":"2003","unstructured":"Schmook T, Nindl I, Ulrich C, Meyer T, Sterry W, Stockfleth E. Viral warts in organ transplant recipients: new aspects in therapy. Br J Dermatol. 2003;149(Suppl 66):20\u20134.","journal-title":"Br J Dermatol"},{"key":"830_CR117","doi-asserted-by":"publisher","first-page":"261","DOI":"10.5021\/ad.2013.25.2.261","volume":"25","author":"SY Kim","year":"2013","unstructured":"Kim SY, Jung SK, Lee SG, Yi SM, Kim JH, Kim IH. New alternative combination therapy for recalcitrant common warts: the efficacy of imiquimod 5% cream and duct tape combination therapy. Ann Dermatol. 2013;25:261\u20133.","journal-title":"Ann Dermatol"},{"key":"830_CR118","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13572","volume":"23","author":"MH Erkayman","year":"2021","unstructured":"Erkayman MH, Bilen H. Clearance of longstanding treatment-resistant warts during COVID-19 in a transplant recipient. Transpl Infect Dis. 2021;23:e13572.","journal-title":"Transpl Infect Dis"},{"key":"830_CR119","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1111\/pde.12992","volume":"34","author":"SE Henrickson","year":"2017","unstructured":"Henrickson SE, Treat JR. Topical cidofovir for recalcitrant verrucae in individuals with severe combined immunodeficiency after hematopoietic stem cell transplantation. Pediatr Dermatol. 2017;34:e24-5.","journal-title":"Pediatr Dermatol"},{"key":"830_CR120","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.bbmt.2018.01.019","volume":"24","author":"JP Hwang","year":"2018","unstructured":"Hwang JP, Ahmed S, Ariza-Heredia EJ, Duan Z, Zhao H, Schmeler KM, et al. Low rate of cervical cancer screening among women with hematologic malignancies after stem cell transplant. Biol Blood Marrow Transplant. 2018;24:1094\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"830_CR121","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1002\/cam4.729","volume":"5","author":"G Dyer","year":"2016","unstructured":"Dyer G, Larsen SR, Gilroy N, Brice L, Greenwood M, Hertzberg M, et al. Adherence to cancer screening guidelines in Australian survivors of allogeneic blood and marrow transplantation (BMT). Cancer Med. 2016;5:1702\u201316.","journal-title":"Cancer Med"},{"key":"830_CR122","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/LGT.0000000000000866","volume":"29","author":"AB Moscicki","year":"2025","unstructured":"Moscicki AB, Flowers L, Huchko MJ, Long ME, MacLaughlin KL, Murphy J, Spiryda LB, Scheckel CJ, Gold MA. Updated review for guidelines for cervical cancer screening in immunosuppressed women without HIV infection. J Low Genit Tract Dis. 2025;29:168\u201379.","journal-title":"J Low Genit Tract Dis"},{"key":"830_CR123","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s10875-018-0558-z","volume":"38","author":"G Bucciol","year":"2018","unstructured":"Bucciol G, Moens L, Payne K, Wollants E, Mekahli D, Levtchenko E, et al. Chronic Aichi virus infection in a patient with X-linked agammaglobulinemia. J Clin Immunol. 2018;38:748\u201352.","journal-title":"J Clin Immunol"},{"key":"830_CR124","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s10875-022-01410-6","volume":"43","author":"I Meyts","year":"2023","unstructured":"Meyts I, Bucciol G, Jansen K, Wollants E, Breuer J. Aichivirus: an emerging pathogen in patients with primary and secondary B-cell deficiency. J Clin Immunol. 2023;43:532\u20135.","journal-title":"J Clin Immunol"},{"key":"830_CR125","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s10875-022-01314-5","volume":"42","author":"Z Bekassy","year":"2022","unstructured":"Bekassy Z, Ehinger M, Pronk LN, Pronk CJ. Immunologic control of disseminated Aichi virus infection in X-linked agammaglobulinemia by transplantation of Tcr\u03b1\u03b2-depleted haploidentical hematopoietic cells. J Clin Immunol. 2022;42:1401\u20134.","journal-title":"J Clin Immunol"},{"key":"830_CR126","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1093\/cid\/ciad237","volume":"77","author":"J Fourgeaud","year":"2023","unstructured":"Fourgeaud J, Lecuit MM, P\u00e9rot P, Bruneau J, Regnault B, Da Rocha N, et al. Chronic Aichi virus infection as a cause of long-lasting multiorgan involvement in patients with primary immune deficiencies. Clin Infect Dis. 2023;77:620\u20138.","journal-title":"Clin Infect Dis"},{"key":"830_CR127","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/S2666-5247(20)30172-5","volume":"2","author":"M Cevik","year":"2021","unstructured":"Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 2021;2:e13-22.","journal-title":"Lancet Microbe"},{"key":"830_CR128","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jinf.2023.01.024","volume":"86","author":"SW Kang","year":"2023","unstructured":"Kang SW, Kim JW, Kim JY, Lim SY, Jang CY, Chang E, et al. Characteristics and risk factors of prolonged viable virus shedding in immunocompromised patients with COVID-19: a prospective cohort study. J Infect. 2023;86:412\u20134.","journal-title":"J Infect"},{"key":"830_CR129","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40472-022-00385-y","volume":"9","author":"V Dioverti","year":"2022","unstructured":"Dioverti V, Salto-Alejandre S, Haidar G. Immunocompromised patients with protracted COVID-19: a review of long persisters. Curr Transpl Rep. 2022;9:209\u201318.","journal-title":"Curr Transpl Rep"},{"key":"830_CR130","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1016\/S1473-3099(23)00815-0","volume":"24","author":"HM Machkovech","year":"2024","unstructured":"Machkovech HM, Hahn AM, Garonzik Wang J, Grubaugh ND, Halfmann PJ, Johnson MC, et al. Persistent SARS-CoV-2 infection: significance and implications. Lancet Infect Dis. 2024;24:e453-62.","journal-title":"Lancet Infect Dis"},{"key":"830_CR131","unstructured":"Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, McCorkell L, Nadkarni GN, Parthasarathy S, Singh U, Walker TA, Selvaggi CA, Shinnick DJ, Schulte CCM, Atchley-Challenner R, Alba GA, Alicic R, Altman N, Anglin K, Argueta U, Ashktorab H, Baslet G, Bassett IV, Bateman L, Bedi B, Bhattacharyya S, Bind MA, Blomkalns AL, Bonilla H, Brim H, Bush PA, Castro M, Chan J, Charney AW, Chen P, Chibnik LB, Chu HY, Clifton RG, Costantine MM, Cribbs SK, Davila Nieves SI, Deeks SG, Duven A, Emery IF, Erdmann N, Erlandson KM, Ernst KC, Farah-Abraham R, Farner CE, Feuerriegel EM, Fleurimont J, Fonseca V, Franko N, Gainer V, Gander JC, Gardner EM, Geng LN, Gibson KS, Go M, Goldman JD, Grebe H, Greenway FL, Habli M, Hafner J, Han JE, Hanson KA, Heath J, Hernandez C, Hess R, Hodder SL, Hoffman MK, Hoover SE, Huang B, Hughes BL, Jagannathan P, John J, Jordan MR, Katz SD, Kaufman ES, Kelly JD, Kelly SW, Kemp MM, Kirwan JP, Klein JD, Knox KS, Krishnan JA, Kumar A, Laiyemo AO, Lambert AA, Lanca M, Lee-Iannotti JK, Logarbo BP, Longo MT, Luciano CA, Lutrick K, Maley JH, Mallett G, Marathe JG, Marconi V, Marshall GD, Martin CF, Matusov Y, Mehari A, Mendez-Figueroa H, Mermelstein R, Metz TD, Morse R, Mosier J, Mouchati C, Mullington J, Murphy SN, Neuman RB, Nikolich JZ, Ofotokun I, Ojemakinde E, Palatnik A, Palomares K, Parimon T, Parry S, Patterson JE, Patterson TF, Patzer RE, Peluso MJ, Pemu P, Pettker CM, Plunkett BA, Pogreba-Brown K, Poppas A, Quigley JG, Reddy U, Reece R, Reeder H, Reeves WB, Reiman EM, Rischard F, Rosand J, Rouse DJ, Ruff A, Saade G, Sandoval GJ, Santana JL, Schlater SM, Sciurba FC, Shepherd F, Sherif ZA, Simhan H, Singer NG, Skupski DW, Sowles A, Sparks JA, Sukhera FI, Taylor BS, Teunis L, Thomas RJ, Thorp JM, Thuluvath P, Ticotsky A, Tita AT, Tuttle KR, Urdaneta AE, Valdivieso D, VanWagoner TM, Vasey A, Verduzco-Gutierrez M, Wallace ZS, Ward HD, Warren DE, Weiner SJ, Welch S, Whiteheart SW, Wiley Z, Wisnivesky JP, Yee LM, Zisis S, Horwitz LI, Foulkes AS; RECOVER Consortium. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA. 2023;329:1934\u20131946."},{"key":"830_CR132","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jaci.2021.10.031","volume":"149","author":"LK Brown","year":"2022","unstructured":"Brown LK, Moran E, Goodman A, Baxendale H, Bermingham W, Buckland M, AbdulKhaliq I, Jarvis H, Hunter M, Karanam S, Patel A, Jenkins M, Robbins A, Khan S, Simpson T, Jolles S, Underwood J, Savic S, Richter A, Shields A, Brown M, Lowe DM. Treatment of chronic or relapsing COVID-19 in immunodeficiency. J Allergy Clin Immunol. 2022;149:557\u2013e5611.","journal-title":"J Allergy Clin Immunol"},{"key":"830_CR133","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/cid\/ciac868","volume":"76","author":"ES Ford","year":"2023","unstructured":"Ford ES, Simmons W, Karmarkar EN, Yoke LH, Braimah AB, Orozco JJ, et al. Successful treatment of prolonged, severe coronavirus disease 2019 lower respiratory tract disease in a B cell acute lymphoblastic leukemia patient with an extended course of Remdesivir and Nirmatrelvir\/Ritonavir. Clin Infect Dis. 2023;76:926\u20139.","journal-title":"Clin Infect Dis"},{"key":"830_CR134","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad189","volume":"10","author":"M Breeden","year":"2023","unstructured":"Breeden M, Aitken SL, Baang JH, Gravelin M, Kaul DR, Lauring AS, et al. Successful treatment of prolonged severe acute respiratory syndrome coronavirus 2 infection in patients with immunodeficiency with extended Nirmatrelvir\/Ritonavir: case series. Open Forum Infect Dis. 2023;10:ofad189.","journal-title":"Open Forum Infect Dis"},{"key":"830_CR135","doi-asserted-by":"publisher","first-page":"e02118","DOI":"10.1016\/j.idcr.2024.e02118","volume":"38","author":"AC Bay","year":"2024","unstructured":"Bay AC, Clausen MR, R\u00f8ge BT, Sydenham TV, Steinke K, Pedersen RM, et al. Antiviral combination treatment of SARS-CoV-2 after repeated treatment failures of Remdesivir monotherapy: a case report. IDCases. 2024;38:e02118.","journal-title":"IDCases"},{"key":"830_CR136","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ijid.2023.04.412","volume":"133","author":"D Marangoni","year":"2023","unstructured":"Marangoni D, Antonello RM, Coppi M, Palazzo M, Nassi L, Streva N, et al. Combination regimen of nirmatrelvir\/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: a case report and a scoping review of the literature. Int J Infect Dis. 2023;133:53\u20136.","journal-title":"Int J Infect Dis"},{"key":"830_CR137","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1093\/cid\/ciad368","volume":"77","author":"V Upasani","year":"2023","unstructured":"Upasani V, Townsend K, Wu MY, Carr EJ, Hobbs A, Dowgier G, et al. Commercial immunoglobulin products contain neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 spike protein. Clin Infect Dis. 2023;77:950\u201360.","journal-title":"Clin Infect Dis"},{"key":"830_CR138","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S1473-3099(24)00353-0","volume":"24","author":"MH Choi","year":"2024","unstructured":"Choi MH, Wan EYF, Wong ICK, Chan EWY, Chu WM, Tam AR, et al. Comparative effectiveness of combination therapy with nirmatrelvir-ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir-ritonavir in patients hospitalised with COVID-19: a target trial emulation study. Lancet Infect Dis. 2024;24:1213\u201324.","journal-title":"Lancet Infect Dis"},{"key":"830_CR139","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.jaip.2020.08.016","volume":"9","author":"MJ Ponsford","year":"2021","unstructured":"Ponsford MJ, Price C, Farewell D, Greene G, Moore C, Perry M, Price N, Cottrell S, Steven R, El-Shanawany T, Carne E, Cousins R, Williams P, Schaub A, Vonarburg C, Jolles S. Increased respiratory viral detection and symptom burden among patients with primary antibody deficiency: results from the BIPAD study. J Allergy Clin Immunol Pract. 2021;9:735\u2013e7446.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"830_CR140","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jaci.2010.04.016","volume":"126","author":"L Kainulainen","year":"2010","unstructured":"Kainulainen L, Vuorinen T, Rantakokko-Jalava K, Osterback R, Ruuskanen O. Recurrent and persistent respiratory tract viral infections in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol. 2010;126:120\u20136.","journal-title":"J Allergy Clin Immunol"},{"key":"830_CR141","doi-asserted-by":"publisher","first-page":"E322","DOI":"10.1111\/1469-0691.12193","volume":"19","author":"V Peltola","year":"2013","unstructured":"Peltola V, Waris M, Kainulainen L, Kero J, Ruuskanen O. Virus shedding after human rhinovirus infection in children, adults and patients with hypogammaglobulinaemia. Clin Microbiol Infect. 2013;19:E322-7.","journal-title":"Clin Microbiol Infect"},{"key":"830_CR142","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/vim.2022.0135","volume":"36","author":"C Santiago-Olivares","year":"2023","unstructured":"Santiago-Olivares C, Mart\u00ednez-Alvarado E, Rivera-Toledo E. Persistence of RNA viruses in the respiratory tract: an overview. Viral Immunol. 2023;36:3\u201312.","journal-title":"Viral Immunol"},{"key":"830_CR143","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1164\/rccm.201302-0341OC","volume":"188","author":"PL Molyneaux","year":"2013","unstructured":"Molyneaux PL, Mallia P, Cox MJ, Footitt J, Willis-Owen SA, Homola D, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188:1224\u201331.","journal-title":"Am J Respir Crit Care Med"},{"key":"830_CR144","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/cid\/ciu169","volume":"58","author":"O Ruuskanen","year":"2014","unstructured":"Ruuskanen O, Waris M, Kainulainen L. Treatment of persistent rhinovirus infection with pegylated interferon \u03b12a and ribavirin in patients with hypogammaglobulinemia. Clin Infect Dis. 2014;58:1784\u20136.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"830_CR145","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/INF.0000000000004321","volume":"43","author":"BL Cinicola","year":"2024","unstructured":"Cinicola BL, Uva A, Duse M, Zicari AM, Buonsenso D. Mucocutaneous candidiasis: insights into the diagnosis and treatment. Pediatr Infect Dis J. 2024;43(7):694\u2013703.","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"830_CR146","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1111\/myc.13371","volume":"64","author":"W Zhang","year":"2021","unstructured":"Zhang W, Wu S, Wang X, Gao Y, Yan Z. Malignant transformation and treatment recommendations of chronic hyperplastic candidiasis-a six-year retrospective cohort study. Mycoses. 2021;64(11):1422\u20138.","journal-title":"Mycoses"},{"issue":"5","key":"830_CR147","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1177\/2050640616684404","volume":"5","author":"S Koo","year":"2017","unstructured":"Koo S, Kejariwal D, Al-Shehri T, Dhar A, Lilic D. Oesophageal candidiasis and squamous cell cancer in patients with gain-of-function STAT1 gene mutation. United Eur Gastroenterol J. 2017;5(5):625\u201331.","journal-title":"United Eur Gastroenterol J"},{"issue":"2","key":"830_CR148","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1046\/j.1468-1293.2001.00060.x","volume":"2","author":"DE Smith","year":"2001","unstructured":"Smith DE, Bell J, Johnson M, Youle M, Gazzard B, Tchamouroff S, Frechette G, Schlech W, Miller S, Spencer D, Seifert W, Peeters M, De Beule K, Itraconazole Prophylaxis Study Group. A randomized, double-blind, placebo-controlled study of Itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV infection. HIV Med. 2001;2(2):78\u201383.","journal-title":"HIV Med"},{"issue":"5","key":"830_CR149","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1016\/S1473-3099(24)00749-7","volume":"25","author":"OA Cornely","year":"2025","unstructured":"Cornely OA, Sprute R, Bassetti M, Chen SC, Groll AH, Kurzai O, Lass-Fl\u00f6rl C, Ostrosky-Zeichner L, Rautemaa-Richardson R, Revathi G, Santolaya ME, White PL, Alastruey-Izquierdo A, Arendrup MC, Baddley J, Barac A, Ben-Ami R, Brink AJ, Grothe JH, Guinea J, Hagen F, Hochhegger B, Hoenigl M, Husain S, Jabeen K, Jensen HE, Kanj SS, Koehler P, Lehrnbecher T, Lewis RE, Meis JF, Nguyen MH, Pana ZD, Rath PM, Reinhold I, Seidel D, Takazono T, Vinh DC, Zhang SX, Afeltra J, Al-Hatmi AMS, Arastehfar A, Arikan-Akdagli S, Bongomin F, Carlesse F, Chayakulkeeree M, Chai LYA, Chamani-Tabriz L, Chiller T, Chowdhary A, Clancy CJ, Colombo AL, Cortegiani A, Corzo Leon DE, Drgona L, Dudakova A, Farooqi J, Gago S, Ilkit M, Jenks JD, Klimko N, Krause R, Kumar A, Lagrou K, Lionakis MS, Lmimouni BE, Mansour MK, Meletiadis J, Mellinghoff SC, Mer M, Mikulska M, Montravers P, Neoh CF, Ozenci V, Pagano L, Pappas P, Patterson TF, Puerta-Alcalde P, Rahimli L, Rahn S, Roilides E, Rotstein C, Ruegamer T, Sabino R, Salmanton-Garc\u00eda J, Schwartz IS, Segal E, Sidharthan N, Singhal T, Sinko J, Soman R, Spec A, Steinmann J, Stemler J, Taj-Aldeen SJ, Talento AF, Thompson GR 3rd, Toebben C, Villanueva-Lozano H, Wahyuningsih R, Weinbergerov\u00e1 B, Wiederhold N, Willinger B, Woo PCY, Zhu LP. Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infect Dis. 2025;25(5):e280\u201393. https:\/\/doi.org\/10.1016\/S1473-3099(24)00749-7.","journal-title":"Lancet Infect Dis."},{"issue":"5","key":"830_CR150","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1128\/JCM.00026-11","volume":"49","author":"BA McManus","year":"2011","unstructured":"McManus BA, McGovern E, Moran GP, Healy CM, Nunn J, Fleming P, et al. Microbiological screening of Irish patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy reveals persistence of Candida albicans strains, gradual reduction in susceptibility to azoles, and incidences of clinical signs of oral candidiasis without culture evidence. J Clin Microbiol. 2011;49(5):1879\u201389.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"830_CR151","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/jac\/dkm299","volume":"60","author":"R Rautemaa","year":"2007","unstructured":"Rautemaa R, Richardson M, Pfaller M, Koukila-K\u00e4hk\u00f6l\u00e4 P, Perheentupa J, Sax\u00e9n H. Decreased susceptibility of Candida albicans to azole antifungals: a complication of long-term treatment in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients. J Antimicrob Chemother. 2007;60(4):889\u201392.","journal-title":"J Antimicrob Chemother"},{"key":"830_CR152","doi-asserted-by":"crossref","unstructured":"Goje O, Azie NE, Angulo DA, Sobel R, Nyirjesy P, Sobel JD. A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2025:S0002-9378(25)00520-4.","DOI":"10.1016\/j.ajog.2025.07.040"},{"issue":"6","key":"830_CR153","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1007\/s10875-023-01519-2","volume":"43","author":"C Melenotte","year":"2023","unstructured":"Melenotte C, Ratiney R, Hermine O, Bougnoux ME, Lanternier F. Successful Rezafungin treatment of an Azole-resistant chronic mucocutaneous candidiasis in a STAT-1 gain-of-function patient. J Clin Immunol. 2023;43(6):1182\u20134.","journal-title":"J Clin Immunol"},{"issue":"1","key":"830_CR154","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10875-023-01629-x","volume":"44","author":"R L\u00e9vy","year":"2023","unstructured":"L\u00e9vy R, Escudier A, Bastard P, Briand C, Polivka L, Stoupa A, Talbotec C, Rothenbuhler A, Charbit M, Debray D, Bodemer C, Casanova JL, Linglart A, Neven B. Ruxolitinib rescues multiorgan clinical autoimmunity in patients with APS-1. J Clin Immunol. 2023;44(1):5.","journal-title":"J Clin Immunol"},{"issue":"20","key":"830_CR155","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1056\/NEJMoa2312665","volume":"390","author":"V Oikonomou","year":"2024","unstructured":"Oikonomou V, Smith G, Constantine GM, Schmitt MM, Ferr\u00e9 EMN, Alejo JC, Riley D, Kumar D, Dos Santos Dias L, Pechacek J, Hadjiyannis Y, Webb T, Seifert BA, Ghosh R, Walkiewicz M, Martin D, Besnard M, Snarr BD, Deljookorani S, Lee CR, DiMaggio T, Barber P, Rosen LB, Cheng A, Rastegar A, de Jesus AA, Stoddard J, Kuehn HS, Break TJ, Kong HH, Castelo-Soccio L, Colton B, Warner BM, Kleiner DE, Quezado MM, Davis JL, Fennelly KP, Olivier KN, Rosenzweig SD, Suffredini AF, Anderson MS, Swidergall M, Guillonneau C, Notarangelo LD, Goldbach-Mansky R, Neth O, Monserrat-Garcia MT, Valverde-Fernandez J, Lucena JM, Gomez-Gila AL, Garcia Rojas A, Sepp\u00e4nen MRJ, Lohi J, Hero M, Laakso S, Klemetti P, Lundberg V, Ekwall O, Olbrich P, Winer KK, Afzali B, Moutsopoulos NM, Holland SM, Heller T, Pittaluga S, Lionakis MS. The role of Interferon-\u03b3 in autoimmune polyendocrine syndrome type 1. N Engl J Med. 2024;390(20):1873\u201384.","journal-title":"N Engl J Med"},{"issue":"5","key":"830_CR156","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10875-022-01257-x","volume":"42","author":"A Dey\u00e0-Mart\u00ednez","year":"2022","unstructured":"Dey\u00e0-Mart\u00ednez A, Rivi\u00e8re JG, Roxo-Junior P, Ramakers J, Bloomfield M, Guisado Hernandez P, et al. Impact of JAK inhibitors in pediatric patients with STAT1 gain of function (GOF) mutations-10 children and review of the literature. J Clin Immunol. 2022;42(5):1071\u201382.","journal-title":"J Clin Immunol"},{"issue":"1","key":"830_CR157","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jaci.2023.10.018","volume":"153","author":"M Fischer","year":"2024","unstructured":"Fischer M, Olbrich P, Hadjadj J, Aumann V, Bakhtiar S, Barlogis V, von Bismarck P, Bloomfield M, Booth C, Buddingh EP, Cagdas D, Castelle M, Chan AY, Chandrakasan S, Chetty K, Cougoul P, Crickx E, Dara J, Dey\u00e0-Mart\u00ednez A, Farmand S, Formankova R, Gennery AR, Gonzalez-Granado LI, Hagin D, Hanitsch LG, Hanzlikov\u00e0 J, Hauck F, Ivorra-Cort\u00e9s J, Kisand K, Kiykim A, K\u00f6rholz J, Leahy TR, van Montfrans J, Nademi Z, Nelken B, Parikh S, Plado S, Ramakers J, Redlich A, Rieux-Laucat F, Rivi\u00e8re JG, Rodina Y, J\u00fanior PR, Salou S, Schuetz C, Shcherbina A, Slatter MA, Touzot F, Unal E, Lankester AC, Burns S, Sepp\u00e4nen MRJ, Neth O, Albert MH, Ehl S, Neven B, Speckmann C. JAK inhibitor treatment for inborn errors of JAK\/STAT signaling: an ESID\/EBMT-IEWP retrospective study. J Allergy Clin Immunol. 2024;153(1):275\u2013e28618.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"830_CR158","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","volume":"18","author":"MA Adas","year":"2022","unstructured":"Adas MA, Alveyn E, Cook E, Dey M, Galloway JB, Bechman K. The infection risks of JAK inhibition. Expert Rev Clin Immunol. 2022;18(3):253\u201361.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"830_CR159","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaci.2017.03.049","volume":"141","author":"JW Leiding","year":"2018","unstructured":"Leiding JW, Okada S, Hagin D, Abinun M, Shcherbina A, Balashov DN, Kim VHD, Ovadia A, Guthery SL, Pulsipher M, Lilic D, Devlin LA, Christie S, Depner M, Fuchs S, van Royen-Kerkhof A, Lindemans C, Petrovic A, Sullivan KE, Bunin N, Kilic SS, Arpaci F, Calle-Martin O, Martinez-Martinez L, Aldave JC, Kobayashi M, Ohkawa T, Imai K, Iguchi A, Roifman CM, Gennery AR, Slatter M, Ochs HD, Morio T, Torgerson TR, Inborn errors working party of the European society for blood and marrow transplantation and the primary immune deficiency treatment Consortium. Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations. J Allergy Clin Immunol. 2018;141(2):704-e7175.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"830_CR160","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis. 2020;71(6):1367\u201376.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"830_CR161","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/infdis\/jis473","volume":"206","author":"SS Henriet","year":"2012","unstructured":"Henriet SS, Verweij PE, Warris A. Aspergillus nidulans and chronic granulomatous disease: a unique host-pathogen interaction. J Infect Dis. 2012;206(7):1128\u201337.","journal-title":"J Infect Dis"},{"issue":"8","key":"830_CR162","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/cid\/ciu1154","volume":"60","author":"BE Marciano","year":"2015","unstructured":"Marciano BE, Spalding C, Fitzgerald A, Mann D, Brown T, Osgood S, et al. Common severe infections in chronic granulomatous disease. Clin Infect Dis. 2015;60(8):1176\u201383.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"830_CR163","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11092233","volume":"11","author":"AA Justiz-Vaillant","year":"2023","unstructured":"Justiz-Vaillant AA, Williams-Persad AF, Arozarena-Fundora R, Gopaul D, Soodeen S, Asin-Milan O, et al. Chronic granulomatous disease (CGD): commonly associated pathogens, diagnosis and treatment. Microorganisms. 2023;11(9):2233.","journal-title":"Microorganisms"},{"issue":"6","key":"830_CR164","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1183\/09031936.00118414","volume":"45","author":"H Salvator","year":"2015","unstructured":"Salvator H, Mahlaoui N, Catherinot E, Rivaud E, Pilmis B, Borie R, et al. Pulmonary manifestations in adult patients with chronic granulomatous disease. Eur Respir J. 2015;45(6):1613\u201323.","journal-title":"Eur Respir J"},{"issue":"6","key":"830_CR165","first-page":"1082","volume":"4","author":"IP Thomsen","year":"2016","unstructured":"Thomsen IP, Smith MA, Holland SM, Creech CB. A comprehensive approach to the management of children and adults with chronic granulomatous disease. J Allergy Clin Immunol. 2016;4(6):1082\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"830_CR166","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/myc.13019","volume":"63","author":"M Tavakoli","year":"2020","unstructured":"Tavakoli M, Rivero-Menendez O, Abastabar M, Hedayati MT, Sabino R, Siopi M, et al. Genetic diversity and antifungal susceptibility patterns of Aspergillus nidulans complex obtained from clinical and environmental sources. Mycoses. 2020;63(1):78\u201388.","journal-title":"Mycoses"},{"issue":"6","key":"830_CR167","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02965-22","volume":"10","author":"SS Jean","year":"2022","unstructured":"Jean SS, Yang HJ, Hsieh PC, Huang YT, Ko WC, Hsueh PR. Vitro susceptibilities of worldwide isolates of intrapulmonary Aspergillus species and important Candida species in sterile body sites against important antifungals: data from the antimicrobial testing leadership and surveillance program, 2017\u20132020. Microbiol Spectr. 2022;10(6):e0296522.","journal-title":"Microbiol Spectr"},{"key":"830_CR168","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-1-4614-4726-9_3","volume":"764","author":"S Henriet","year":"2013","unstructured":"Henriet S, Verweij PE, Holland SM, Warris A. Invasive fungal infections in patients with chronic granulomatous disease. Adv Exp Med Biol. 2013;764:27\u201355.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"830_CR169","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/INF.0b013e3181f13b23","volume":"30","author":"J Beaut\u00e9","year":"2011","unstructured":"Beaut\u00e9 J, Obenga G, Le Mignot L, Mahlaoui N, Bougnoux ME, Mouy R, Gougerot-Pocidalo MA, Barlogis V, Suarez F, Lanternier F, Hermine O, Lecuit M, Blanche S, Fischer A, Lortholary O, French PID Study Group CEREDIH. Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: a multicenter study in France. Pediatr Infect Dis J. 2011;30(1):57\u201362.","journal-title":"Pediatr Infect Dis J"},{"issue":"24","key":"830_CR170","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa021931","volume":"348","author":"JI Gallin","year":"2003","unstructured":"Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, Eisenstein EM, Turner ML, DeCarlo ES, Starling JM, Holland SM. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med. 2003;348(24):2416\u201322.","journal-title":"N Engl J Med"},{"issue":"2","key":"830_CR171","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1365-2249.2008.03644.x","volume":"152","author":"LB Jones","year":"2008","unstructured":"Jones LB, McGrogan P, Flood TJ, Gennery AR, Morton L, Thrasher A, et al. Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin Exp Immunol. 2008;152(2):211\u20138.","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"830_CR172","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1046\/j.1365-2249.2000.01234.x","volume":"120","author":"CM Cale","year":"2000","unstructured":"Cale CM, Jones AM, Goldblatt D. Follow up of patients with chronic granulomatous disease diagnosed since 1990. Clin Exp Immunol. 2000;120(2):351\u20135.","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"830_CR173","doi-asserted-by":"publisher","DOI":"10.1111\/myc.70086","volume":"68","author":"Z Ergenc","year":"2025","unstructured":"Ergenc Z, Eltan SB, Karaaslan BG, Kiykim A, Tuncay SA, Yilmaz S, et al. Invasive mould infections in chronic granulomatous disease: a multicenter study from T\u00fcrkiye. Mycoses. 2025;68(7):e70086.","journal-title":"Mycoses"},{"issue":"12","key":"830_CR174","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1093\/cid\/cir731","volume":"53","author":"S Blumental","year":"2011","unstructured":"Blumental S, Mouy R, Mahlaoui N, Bougnoux ME, Debr\u00e9 M, Beaut\u00e9 J, Lortholary O, Blanche S, Fischer A. Invasive mold infections in chronic granulomatous disease: a 25-year retrospective survey. Clin Infect Dis. 2011;53(12):e159\u201369.","journal-title":"Clin Infect Dis"},{"key":"830_CR175","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.2147\/IDR.S170706","volume":"11","author":"J Zhang","year":"2018","unstructured":"Zhang J, Liu Y, Nie X, Yu Y, Gu J, Zhao L. Trough concentration of itraconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. Infect Drug Resist. 2018;11:1283\u201397.","journal-title":"Infect Drug Resist"},{"issue":"4","key":"830_CR176","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63(4):e1\u201360.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"830_CR177","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/jac\/dkt508","volume":"69","author":"HR Ashbee","year":"2014","unstructured":"Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British society for medical mycology. J Antimicrob Chemother. 2014;69(5):1162\u201376.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"830_CR178","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"AJ Ullmann","year":"2018","unstructured":"Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1-38.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"830_CR179","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab502","volume":"8","author":"J Lindsay","year":"2021","unstructured":"Lindsay J, Othman J, Kong Y, Yip A, Van Hal S, Larsen S, et al. SUBA-itraconazole for primary antifungal prophylaxis after allogeneic hematopoietic cell transplantation. Open Forum Infect Dis. 2021;8(11):ofab502.","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"830_CR180","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/jac\/dkad143","volume":"78","author":"J Stemler","year":"2023","unstructured":"Stemler J, Mellinghoff SC, Khodamoradi Y, Sprute R, Classen AY, Zapke SE, et al. Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the infectious diseases working party (AGIHO) of the German society for haematology and medical oncology (DGHO). J Antimicrob Chemother. 2023;78(8):1813\u201326.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"830_CR181","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/cid\/cit940","volume":"58","author":"K Williams","year":"2014","unstructured":"Williams K, Mansh M, Chin-Hong P, Singer J, Arron ST. Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis. 2014;58(7):997\u20131002.","journal-title":"Clin Infect Dis"},{"key":"830_CR182","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10875-024-01798-3","volume":"45","author":"S Xing","year":"2024","unstructured":"Xing S, Zhang Z, Liu C, Zhang W, Zhang Z, Tang X, et al. Characteristics of endemic mycoses talaromyces marneffei infection associated with inborn errors of immunity. J Clin Immunol. 2024;45:17.","journal-title":"J Clin Immunol"},{"key":"830_CR183","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2147\/IDR.S493956","volume":"18","author":"CY Zhao","year":"2025","unstructured":"Zhao CY, Song C, He HW, Huang XZ, Meng XY, Huang AC, et al. Clinical characteristics analysis of 30 cases of Interferon-\u03b3 autoantibody-positive patients with concurrent mycobacterial infection: a 6-year retrospective study. Infect Drug Resist. 2025;18:1097\u2013110.","journal-title":"Infect Drug Resist"},{"key":"830_CR184","first-page":"1371","volume":"8","author":"S Fekrvand","year":"2020","unstructured":"Fekrvand S, Yazdani R, Olbrich P, Gennery A, Rosenzweig SD, Condino-Neto A, et al. Primary immunodeficiency diseases and Bacillus Calmette-Gu\u00e9rin (BCG)-vaccine-derived complications: a systematic review. The Journal of Allergy and Clinical Immunology: In Practice. 2020;8:1371\u201386.","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"},{"key":"830_CR185","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.jaci.2024.01.021","volume":"153","author":"A Khavandegar","year":"2024","unstructured":"Khavandegar A, Mahdaviani SA, Zaki-Dizaji M, Khalili-Moghaddam F, Ansari S, Alijani S, et al. Genetic, immunologic, and clinical features of 830 patients with Mendelian susceptibility to mycobacterial diseases (MSMD): a systematic review. J Allergy Clin Immunol. 2024;153:1432\u201344.","journal-title":"J Allergy Clin Immunol"},{"key":"830_CR186","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.urolonc.2020.11.037","volume":"39","author":"P Cabas","year":"2021","unstructured":"Cabas P, Rizzo M, Giuffr\u00e8 M, Antonello RM, Trombetta C, Luzzati R, et al. BCG infection (BCGitis) following intravesical instillation for bladder cancer and time interval between treatment and presentation: a systematic review. Urol Oncol. 2021;39:85\u201392.","journal-title":"Urol Oncol"},{"key":"830_CR187","doi-asserted-by":"publisher","first-page":"625320","DOI":"10.3389\/fimmu.2021.625320","volume":"12","author":"A Rawat","year":"2021","unstructured":"Rawat A, Vignesh P, Sudhakar M, Sharma M, Suri D, Jindal A, et al. Clinical, immunological, and molecular profile of chronic granulomatous disease: a multi-centric study of 236 patients from India. Front Immunol. 2021;12:625320.","journal-title":"Front Immunol"},{"key":"830_CR188","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jaci.2015.11.041","volume":"138","author":"F Conti","year":"2016","unstructured":"Conti F, Lugo-Reyes SO, Blancas Galicia L, He J, Aksu G, Borges de Oliveira E Jr, Deswarte C, Hubeau M, Karaca N, de Suremain M, Gu\u00e9rin A, Baba LA, Prando C, Guerrero GG, Emiroglu M, \u00d6z FN, Yamazaki Nakashimada MA, Gonzalez Serrano E, Espinosa S, Barlan I, P\u00e9rez N, Regairaz L, Guidos Morales HE, Bezrodnik L, Di Giovanni D, Dbaibo G, Ailal F, Galicchio M, Oleastro M, Chemli J, Danielian S, Perez L, Ortega MC, Soto Lavin S, Hertecant J, Anal O, Kechout N, Al-Idrissi E, ElGhazali G, Bondarenko A, Chernyshova L, Ciznar P, Herbigneaux RM, Diabate A, Ndaga S, Konte B, Czarna A, Migaud M, Pedraza-S\u00e1nchez S, Zaidi MB, Vogt G, Blanche S, Benmustapha I, Mansouri D, Abel L, Boisson-Dupuis S, Mahlaoui N, Bousfiha AA, Picard C, Barbouche R, Al-Muhsen S, Espinosa-Rosales FJ, K\u00fct\u00fck\u00e7\u00fcler N, Condino-Neto A, Casanova JL, Bustamante J. Mycobacterial disease in patients with chronic granulomatous disease: A retrospective analysis of 71 cases. J Allergy Clin Immunol. 2016;138:241\u2013e2483.","journal-title":"J Allergy Clin Immunol"},{"key":"830_CR189","doi-asserted-by":"publisher","first-page":"e1004325","DOI":"10.1371\/journal.ppat.1004325","volume":"10","author":"C Deffert","year":"2014","unstructured":"Deffert C, Sch\u00e4ppi MG, Pache JC, Cachat J, Vesin D, Bisig R, et al. Bacillus calmette-guerin infection in NADPH oxidase deficiency: defective mycobacterial sequestration and granuloma formation. PLoS Pathog. 2014;10:e1004325.","journal-title":"PLoS Pathog"},{"key":"830_CR190","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/INF.0b013e31815b494c","volume":"27","author":"PP Lee","year":"2008","unstructured":"Lee PP, Chan KW, Jiang L, Chen T, Li C, Lee TL, et al. Susceptibility to mycobacterial infections in children with X-linked chronic granulomatous disease: a review of 17 patients living in a region endemic for tuberculosis. Pediatr Infect Dis J. 2008;27:224\u201330.","journal-title":"Pediatr Infect Dis J"},{"key":"830_CR191","doi-asserted-by":"publisher","first-page":"10430","DOI":"10.1073\/pnas.1903561116","volume":"116","author":"G Kerner","year":"2019","unstructured":"Kerner G, Ramirez-Alejo N, Seeleuthner Y, Yang R, Ogishi M, Cobat A, et al. Homozygosity for TYK2 P1104A underlies tuberculosis in about 1% of patients in a cohort of European ancestry. Proc Natl Acad Sci U S A. 2019;116:10430\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"830_CR192","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00431-005-0022-y","volume":"165","author":"R Renella","year":"2006","unstructured":"Renella R, Perez JM, Chollet-Martin S, Sarnacki S, Fischer A, Blanche S, et al. Burkholderia pseudomallei infection in chronic granulomatous disease. Eur J Pediatr. 2006;165:175\u20137.","journal-title":"Eur J Pediatr"},{"key":"830_CR193","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1086\/513928","volume":"26","author":"SE Dorman","year":"1998","unstructured":"Dorman SE, Gill VJ, Gallin JI, Holland SM. Burkholderia pseudomallei infection in a Puerto Rican patient with chronic granulomatous disease: case report and review of occurrences in the Americas. Clin Infect Dis. 1998;26:889\u201394.","journal-title":"Clin Infect Dis"},{"key":"830_CR194","first-page":"19","volume":"64","author":"MJ Tarlow","year":"1971","unstructured":"Tarlow MJ, Lloyd J. Melioidosis and chronic granulomatous disease. Proc R Soc Med. 1971;64:19\u201320.","journal-title":"Proc R Soc Med"},{"key":"830_CR195","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3324\/haematol.2014.121608","volume":"100","author":"SF Bode","year":"2015","unstructured":"Bode SF, Ammann S, Al-Herz W, Bataneant M, Dvorak CC, Gehring S, Gennery A, Gilmour KC, Gonzalez-Granado LI, Gro\u00df-Wieltsch U, Ifversen M, Lingman-Framme J, Matthes-Martin S, Mesters R, Meyts I, van Montfrans JM, Pachlopnik Schmid J, Pai SY, Soler-Palacin P, Schuermann U, Schuster V, Seidel MG, Speckmann C, Stepensky P, Sykora KW, Tesi B, Vraetz T, Waruiru C, Bryceson YT, Moshous D, Lehmberg K, Jordan MB, Ehl S, Inborn errors working party of the EBMT. The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis. Haematologica. 2015;100:978\u201388.","journal-title":"Haematologica"},{"key":"830_CR196","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.7426","volume":"11","author":"S Ashraf Talesh","year":"2023","unstructured":"Ashraf Talesh S, Mahmoudi S, Mohebali M, Mamishi S. A rare presentation of visceral leishmaniasis and epididymo-orchitis in a patient with chronic granulomatous disease. Clin Case Rep. 2023;11:e7426.","journal-title":"Clin Case Rep"},{"key":"830_CR197","first-page":"159","volume":"16","author":"MR Abdolsalehi","year":"2021","unstructured":"Abdolsalehi MR, Mohebali M, Keshavarz H, Mahmoudi S, Mamishi S. The emergence of co-infection of visceral leishmaniasis in an Iranian child with chronic granulomatous disease: a case report. Iran J Parasitol. 2021;16:159\u201363.","journal-title":"Iran J Parasitol"},{"key":"830_CR198","doi-asserted-by":"publisher","first-page":"127","DOI":"10.12688\/f1000research.130272.2","volume":"12","author":"SK Ahmed","year":"2023","unstructured":"Ahmed SK, Mohamed MG, Dabou EA, Abuijlan I, Chandran D, El-Shall NA, Chopra H, Dhama K. Monkeypox (mpox) in immunosuppressed patients. F1000Res. 2023;12:127.","journal-title":"F1000Res"},{"key":"830_CR199","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40265-024-02117-1","volume":"85","author":"Y Rizk","year":"2025","unstructured":"Rizk Y, Lippi G, Henry BM, Notarte KI, Rizk JG. Update on Mpox management: epidemiology, vaccines and therapeutics, and regulatory changes. Drugs. 2025;85:1\u20139.","journal-title":"Drugs"},{"key":"830_CR200","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.15585\/mmwr.mm7145a4","volume":"71","author":"CM Kava","year":"2022","unstructured":"Kava CM, Rohraff DM, Wallace B, Mendoza-Alonzo JL, Currie DW, Munsey AE, et al. Epidemiologic features of the Monkeypox outbreak and the public health response - United States, May 17-October 6, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:1449\u201356.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"830_CR201","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28644","volume":"95","author":"A Saghazadeh","year":"2023","unstructured":"Saghazadeh A, Rezaei N. Inborn errors of immunity and worries during the Monkeypox outbreak. J Med Virol. 2023;95:e28644.","journal-title":"J Med Virol"},{"issue":"5","key":"830_CR202","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3892\/mmr.2023.12991","volume":"27","author":"Q Liu","year":"2023","unstructured":"Liu Q, Jin X, Cheng J, Zhou H, Zhang Y, Dai Y. Advances in the application of molecular diagnostic techniques for the detection of infectious disease pathogens (Review). Mol Med Rep. 2023;27(5):104.","journal-title":"Mol Med Rep"},{"issue":"1","key":"830_CR203","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12879-021-06968-x","volume":"22","author":"X Tian","year":"2022","unstructured":"Tian X, Shi Q, Liu P, Pang L, Jia P, Xie L, et al. Overlapping infection of nocardia farcinica and Aspergillus fumigatus in a child with X-linked chronic granulomatous disease: a case report. BMC Infect Dis. 2022;22(1):69.","journal-title":"BMC Infect Dis"},{"key":"830_CR204","doi-asserted-by":"publisher","first-page":"696403","DOI":"10.3389\/fimmu.2021.696403","volume":"12","author":"W Tang","year":"2021","unstructured":"Tang W, Zhang Y, Luo C, Zhou L, Zhang Z, Tang X, Zhao X, An Y. Clinical application of metagenomic next-generation sequencing for suspected infections in patients with primary immunodeficiency disease. Front Immunol. 2021;12:696403.","journal-title":"Front Immunol"},{"issue":"1","key":"830_CR205","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s10875-025-01878-y","volume":"45","author":"J Maimaris","year":"2025","unstructured":"Maimaris J, Payne J, Roa-Bautista A, Breuer J, Storey N, Morfopoulou S, et al. Safety and diagnostic utility of brain biopsy and metagenomics in decision-making for patients with inborn errors of immunity (IEI) and unexplained neurological manifestations. J Clin Immunol. 2025;45(1):86.","journal-title":"J Clin Immunol"},{"key":"830_CR206","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jaci.2019.01.051","volume":"144","author":"C Milito","year":"2019","unstructured":"Milito C, Pulvirenti F, Cinetto F, Lougaris V, Soresina A, Pecoraro A, Vultaggio A, Carrabba M, Lassandro G, Plebani A, Spadaro G, Matucci A, Fabio G, Dellepiane RM, Martire B, Agostini C, Abeni D, Tabolli S, Quinti I. Double-blind, placebo-controlled, randomized trial on low-dose Azithromycin prophylaxis in patients with primary antibody deficiencies. J Allergy Clin Immunol. 2019;144:584\u2013e5937.","journal-title":"J Allergy Clin Immunol"},{"key":"830_CR207","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/eji.202048713","volume":"50","author":"L Hanitsch","year":"2020","unstructured":"Hanitsch L, Baumann U, Boztug K, Burkhard-Meier U, Fasshauer M, Habermehl P, et al. Treatment and management of primary antibody deficiency: German interdisciplinary evidence-based consensus guideline. Eur J Immunol. 2020;50:1432\u201346.","journal-title":"Eur J Immunol"},{"key":"830_CR208","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.clim.2009.10.003","volume":"135","author":"PL Yong","year":"2010","unstructured":"Yong PL, Boyle J, Ballow M, Boyle M, Berger M, Bleesing J, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the primary immunodeficiency committee of the American academy of allergy asthma and immunology. Clin Immunol. 2010;135:255\u201363.","journal-title":"Clin Immunol"},{"key":"830_CR209","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/S0140-6736(07)60235-9","volume":"369","author":"S Malhotra-Kumar","year":"2007","unstructured":"Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant Streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet. 2007;369:482\u201390.","journal-title":"Lancet"},{"key":"830_CR210","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2021.102095","volume":"71","author":"J Pollock","year":"2021","unstructured":"Pollock J, Chalmers JD. The immunomodulatory effects of macrolide antibiotics in respiratory disease. Pulm Pharmacol Ther. 2021;71:102095.","journal-title":"Pulm Pharmacol Ther"},{"key":"830_CR211","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1586\/1744666X.2015.1075396","volume":"11","author":"P Mohammadinejad","year":"2015","unstructured":"Mohammadinejad P, Ataeinia B, Kaynejad K, Zeinoddini A, Sadeghi B, Hosseini M, Rezaei N, Aghamohammadi A. Antibiotic resistance in patients with primary immunodeficiency disorders versus immunocompetent patients. Expert Rev Clin Immunol. 2015;11:1163\u201372.","journal-title":"Expert Rev Clin Immunol"},{"key":"830_CR212","doi-asserted-by":"crossref","unstructured":"Karabiber E, Ilki A, G\u00f6kdemir Y, Vatansever HM, Olgun Y\u0131ld\u0131zeli \u015e, Ozen A. Microbial isolates and antimicrobial resistance patterns in adults with inborn errors of immunity: A retrospective longitudinal analysis of sputum cultures. Int Arch Allergy Immunol. 2024:1\u201312.","DOI":"10.1159\/000541533"},{"key":"830_CR213","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad135","volume":"5","author":"S Rofael","year":"2023","unstructured":"Rofael S, Leboreiro Babe C, Davrandi M, Kondratiuk AL, Cleaver L, Ahmed N, et al. Antibiotic resistance, bacterial transmission and improved prediction of bacterial infection in patients with antibody deficiency. JAC-Antimicrobial Resistance. 2023;5:dlad135.","journal-title":"JAC-Antimicrobial Resistance"},{"key":"830_CR214","doi-asserted-by":"publisher","first-page":"1382500","DOI":"10.3389\/fcimb.2024.1382500","volume":"14","author":"S Khafaja","year":"2025","unstructured":"Khafaja S, Salameh Y, Boutros CF, Awad C, Faour K, Tfaily N, Merhi S, Zein ZE, Karroum SB, Oweini D, Fayad D, Araj GF, Zakhour R, Dbaibo GS. Increased rate of multidrug-resistant gram-negative bacterial infections in hospitalized immunocompromised pediatric patients. Front Cell Infect Microbiol. 2025;14:1382500.","journal-title":"Front Cell Infect Microbiol"},{"key":"830_CR215","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jaip.2017.05.024","volume":"6","author":"JM Sperlich","year":"2018","unstructured":"Sperlich JM, Grimbacher B, Workman S, Haque T, Seneviratne SL, Burns SO, Reiser V, Vach W, Hurst JR, Lowe DM. Respiratory infections and antibiotic usage in common variable immunodeficiency. J Allergy Clin Immunol Pract. 2018;6:159\u2013e1683.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"830_CR216","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cgh.2007.02.025","volume":"5","author":"K Katchar","year":"2007","unstructured":"Katchar K, Taylor CP, Tummala S, Chen X, Sheikh J, Kelly CP. Association between IgG2 and IgG3 subclass responses to toxin A and recurrent clostridium difficile-associated disease. Clin Gastroenterol Hepatol. 2007;5:707\u201313.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"830_CR217","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ijid.2008.11.012","volume":"13","author":"J O\u2019Horo","year":"2009","unstructured":"O\u2019Horo J, Safdar N. The role of immunoglobulin for the treatment of clostridium difficile infection: a systematic review. Int J Infect Dis. 2009;13:663\u20137.","journal-title":"Int J Infect Dis"},{"key":"830_CR218","doi-asserted-by":"publisher","first-page":"209","DOI":"10.14740\/gr1624","volume":"16","author":"A Malik","year":"2023","unstructured":"Malik A, Malik MI. Fecal microbiota transplantation in human immunodeficiency Virus-Infected patient population: a systematic review and meta-analysis. Gastroenterol Res. 2023;16:209\u201316.","journal-title":"Gastroenterol Res"},{"key":"830_CR219","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1394379","volume":"2018","author":"O Shogbesan","year":"2018","unstructured":"Shogbesan O, Poudel DR, Victor S, Jehangir A, Fadahunsi O, Shogbesan G, et al. A systematic review of the efficacy and safety of fecal microbiota transplant for Clostridium difficile infection in immunocompromised patients. Can J Gastroenterol Hepatol. 2018;2018:1394379.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"830_CR220","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/MPG.0000000000003714","volume":"76","author":"KR Conover","year":"2023","unstructured":"Conover KR, Absah I, Ballal S, Brumbaugh D, Cho S, Cardenas MC, et al. Fecal microbiota transplantation for clostridioides difficile infection in immunocompromised pediatric patients. J Pediatr Gastroenterol Nutr. 2023;76:440\u20136.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"830_CR221","doi-asserted-by":"publisher","first-page":"1456672","DOI":"10.3389\/fcimb.2024.1456672","volume":"14","author":"K Napi\u00f3rkowska-Baran","year":"2024","unstructured":"Napi\u00f3rkowska-Baran K, Bili\u0144ski J, Pujanek M, Ha\u0142akuc P, Pietryga A, Szymczak B, Deptu\u0142a A, Rosada T, Bartuzi Z. Fecal microbiota transplantation in a patient with chronic diarrhea and primary and secondary immunodeficiency (common variable immunodeficiency and splenectomy). Front Cell Infect Microbiol. 2024;14:1456672.","journal-title":"Front Cell Infect Microbiol"},{"key":"830_CR222","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/idr14010007","volume":"14","author":"B Merrick","year":"2022","unstructured":"Merrick B, Tamilarasan AG, Luber R, Yong PFK, Cheent K, Irving PM, et al. Recurrent Campylobacter jejuni infection in an immunodeficient patient treated with repeated faecal microbiota transplant (FMT)-a case report. Infect Dis Rep. 2022;14:56\u201362.","journal-title":"Infect Dis Rep"},{"key":"830_CR223","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2019.100068","volume":"12","author":"P Shrestha","year":"2019","unstructured":"Shrestha P, Karmacharya P, Wang Z, Donato A, Joshi AY. Impact of IVIG vs. SCIG on IgG trough level and infection incidence in primary immunodeficiency diseases: a systematic review and meta-analysis of clinical studies. World Allergy Organ J. 2019;12:100068.","journal-title":"World Allergy Organ J"},{"key":"830_CR224","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2217\/imt-2021-0265","volume":"14","author":"C Anderson-Smits","year":"2022","unstructured":"Anderson-Smits C, Park M, Bell J, Mitchell S, Hartley L, Hawe E. Subcutaneous immunoglobulin use in immunoglobulin-naive patients with primary immunodeficiency: a systematic review. Immunotherapy. 2022;14:373\u201387.","journal-title":"Immunotherapy"},{"key":"830_CR225","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/13696998.2024.2368987","volume":"27","author":"F Riaz","year":"2024","unstructured":"Riaz F, Umashankar K, Marchlewicz EH, Zhang K, Khandelwal N, Sanchirico M. Initiating immunoglobulin replacement therapy helps reduce severe infections and shifts healthcare resource utilization to outpatient services among US patients with inborn errors of immunity. J Med Econ. 2024;27:849\u201357.","journal-title":"J Med Econ"},{"key":"830_CR226","doi-asserted-by":"crossref","unstructured":"Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency committee of the American academy of allergy, asthma and immunology. J Allergy Clin Immunol. 2006;117(Suppl 4):S525-53.","DOI":"10.1016\/j.jaci.2006.01.015"},{"key":"830_CR227","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/cid\/ciw222","volume":"63","author":"I Ramsay","year":"2016","unstructured":"Ramsay I, Gorton RL, Patel M, Workman S, Symes A, Haque T, et al. Transmission of hepatitis B core antibody and galactomannan enzyme immunoassay positivity via immunoglobulin products: a comprehensive analysis. Clin Infect Dis. 2016;63:57\u201363.","journal-title":"Clin Infect Dis"},{"key":"830_CR228","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/cid\/ciab1028","volume":"75","author":"J Tschopp","year":"2022","unstructured":"Tschopp J, Brunel AS, Spertini O, Croxatto A, Lamoth F, Bochud PY. High false-positive rate of (1,3)-\u03b2-D-glucan in onco-hematological patients receiving immunoglobulins and therapeutic antibodies. Clin Infect Dis. 2022;75:330\u20133.","journal-title":"Clin Infect Dis"},{"key":"830_CR229","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jinf.2017.10.017","volume":"76","author":"M Egger","year":"2018","unstructured":"Egger M, Pr\u00fcller F, Raggam R, Divjak MK, Kurath-Koller S, Lackner H, et al. False positive serum levels of (1\u20133)-\u00df-D-glucan after infusion of intravenous immunoglobulins and time to normalisation. J Infect. 2018;76:206\u201310.","journal-title":"J Infect"},{"key":"830_CR230","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2021.04.019","volume":"134","author":"S De l\u2019\u00c9toile-Morel","year":"2021","unstructured":"De l\u2019\u00c9toile-Morel S, Schweitzer L, Lefebvre MA. False-positive syphilis serologies in a woman receiving intravenous immunoglobulin. Am J Med. 2021;134:e524\u20135.","journal-title":"Am J Med"},{"key":"830_CR231","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.106290","volume":"178","author":"ES Hunter","year":"2021","unstructured":"Hunter ES, Wilopo B, Richardson MD, Kosmidis C, Denning DW. Effect of patient immunodeficiencies on the diagnostic performance of serological assays to detect Aspergillus-specific antibodies in chronic pulmonary aspergillosis. Respir Med. 2021;178:106290.","journal-title":"Respir Med"},{"key":"830_CR232","doi-asserted-by":"publisher","first-page":"634181","DOI":"10.3389\/fimmu.2021.634181","volume":"12","author":"YY Demirdag","year":"2021","unstructured":"Demirdag YY, Gupta S. Update on infections in primary antibody deficiencies. Front Immunol. 2021;12:634181.","journal-title":"Front Immunol"},{"key":"830_CR233","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.cmi.2021.06.020","volume":"27","author":"E Yusuf","year":"2021","unstructured":"Yusuf E, Allerberger F. Infectious disease serology in 2021. Clin Microbiol Infect. 2021;27:1204\u20136.","journal-title":"Clin Microbiol Infect"},{"key":"830_CR234","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.intimp.2014.09.015","volume":"23","author":"DC Bichuetti-Silva","year":"2014","unstructured":"Bichuetti-Silva DC, Furlan FP, Nobre FA, Pereira CT, Gon\u00e7alves TR, Gouveia-Pereira M, et al. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions. Int Immunopharmacol. 2014;23:442\u20136.","journal-title":"Int Immunopharmacol"},{"key":"830_CR235","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1046\/j.1365-2249.2003.02199.x","volume":"133","author":"VM Brennan","year":"2003","unstructured":"Brennan VM, Salom\u00e9-Bentley NJ, Chapel HM, Immunology nurses Study. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous Immunoglobulin. Clin Exp Immunol. 2003;133:247\u201351.","journal-title":"Clin Exp Immunol"},{"issue":"Suppl 3","key":"830_CR236","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2012.07.002","volume":"130","author":"JS Orange","year":"2012","unstructured":"Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M, Kumararatne D, Harville TO, Hesterberg P, Koleilat M, McGhee S, Perez EE, Raasch J, Scherzer R, Schroeder H, Seroogy C, Huissoon A, Sorensen RU, Katial R. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the basic and clinical immunology interest section of the American academy of Allergy, asthma & immunology. J Allergy Clin Immunol. 2012;130(Suppl 3):S1\u201324.","journal-title":"J Allergy Clin Immunol"},{"key":"830_CR237","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","volume":"372","author":"MJ Bonten","year":"2015","unstructured":"Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114\u201325.","journal-title":"N Engl J Med"},{"key":"830_CR238","doi-asserted-by":"crossref","unstructured":"ACIP Updates: Recommendations for use of 20-Valent Pneumococcal conjugate vaccine in Children - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72:1072.","DOI":"10.15585\/mmwr.mm7239a5"},{"key":"830_CR239","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.mm7401a1","volume":"74","author":"M Kobayashi","year":"2025","unstructured":"Kobayashi M, Leidner AJ, Gierke R, Xing W, Accorsi E, Moro P, et al. Expanded recommendations for use of Pneumococcal conjugate vaccines among adults aged\u2009\u2265\u200950 years: recommendations of the advisory committee on immunization practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 2025;74:1\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"830_CR240","first-page":"1","volume":"57","author":"SE Manning","year":"2008","unstructured":"Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lumlertdacha B, Guerra M, Meltzer MI, Dhankhar P, Vaidya SA, Jenkins SR, Sun B, Hull HF, Advisory Committee on Immunization Practices Centers for Disease Control and Prevention (CDC). Human rabies prevention\u2013United States, 2008: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep. 2008;57:1\u201328.","journal-title":"MMWR Recomm Rep"},{"issue":"RR\u20132","key":"830_CR241","first-page":"1","volume":"59","author":"CE Rupprecht","year":"2010","unstructured":"Rupprecht CE, Briggs D, Brown CM, Franka R, Katz SL, Kerr HD, et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep. 2010;59(RR\u20132):1\u20139.","journal-title":"MMWR Recomm Rep"},{"key":"830_CR242","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jaci.2017.12.980","volume":"141","author":"FA Bonilla","year":"2018","unstructured":"Bonilla FA. Update: vaccines in primary immunodeficiency. J Allergy Clin Immunol. 2018;141:474\u201381.","journal-title":"J Allergy Clin Immunol"},{"key":"830_CR243","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.jaip.2016.09.012","volume":"4","author":"A Sobh","year":"2016","unstructured":"Sobh A, Bonilla FA. Vaccination in primary immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016;4:1066\u201375.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"830_CR244","doi-asserted-by":"publisher","first-page":"126853","DOI":"10.1016\/j.vaccine.2025.126853","volume":"51","author":"G Olivieri","year":"2025","unstructured":"Olivieri G, Amodio D, Manno EC, Santilli V, Cotugno N, Palma P. Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies. Vaccine. 2025;51:126853.","journal-title":"Vaccine"},{"key":"830_CR245","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2209604","volume":"388","author":"A Papi","year":"2023","unstructured":"Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstr\u00f8m V, AReSVi-006 study Group. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med. 2023;388:595\u2013608.","journal-title":"N Engl J Med"},{"key":"830_CR246","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","volume":"388","author":"EE Walsh","year":"2023","unstructured":"Walsh EE, P\u00e9rez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, Polack FP, Llapur C, Doreski PA, Ilangovan K, R\u00e4met M, Fukushima Y, Hussen N, Bont LJ, Cardona J, DeHaan E, Castillo Villa G, Ingilizova M, Eiras D, Mikati T, Shah RN, Schneider K, Cooper D, Koury K, Lino MM, Anderson AS, Jansen KU, Swanson KA, Gurtman A, Gruber WC, Schmoele-Thoma B, RENOIR Clinical Trial Group. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med. 2023;388:1465\u201377.","journal-title":"N Engl J Med"},{"key":"830_CR247","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","volume":"389","author":"E Wilson","year":"2023","unstructured":"Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K, et al. Efficacy and safety of an mRNA-based RSV pref vaccine in older adults. N Engl J Med. 2023;389:2233\u201344.","journal-title":"N Engl J Med"},{"key":"830_CR248","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.anpede.2022.03.002","volume":"96","author":"LI Gonz\u00e1lez-Granado","year":"2022","unstructured":"Gonz\u00e1lez-Granado LI, Mart\u00edn-Nalda A, Alsina L, Neth O, Santamar\u00eda M, Soler-Palac\u00edn P, et al. Respiratory syncytial virus infections requiring hospitalization in patients with primary immunodeficiency. Anales de Pediatr\u00eda (English Edition). 2022;96:492\u2013500.","journal-title":"Anales de Pediatr\u00eda (English Edition)"},{"issue":"Suppl 1","key":"830_CR249","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.3949\/ccjm.91.s1.06","volume":"91","author":"CE Koval","year":"2024","unstructured":"Koval CE, Gonzalez BE. RSV in transplant and immunocompromised patients. Cleve Clin J Med. 2024;91(Suppl 1):S34\u201341.","journal-title":"Cleve Clin J Med"},{"key":"830_CR250","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/infdis\/169.6.1368","volume":"169","author":"GR Siber","year":"1994","unstructured":"Siber GR, Leombruno D, Leszczynski J, McIver J, Bodkin D, Gonin R, et al. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis. 1994;169:1368\u201373.","journal-title":"J Infect Dis"},{"key":"830_CR251","unstructured":"Communicable Disease Centre. Vaccines & Immunizations. Adult Immunization Schedule. Recommendations for Ages 19 Years or Older, United States. 2024. https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-schedules\/adult.html Accessed: 18 August 2025."},{"key":"830_CR252","unstructured":"The Green book Chap. 7: Immunisation of individuals with underlying medical conditions. January 2020. https:\/\/assets.publishing.service.gov.uk\/media\/5e18a52940f0b65dc1918763\/Greenbook_chapter_7_Immunsing_immunosupressed.pdf Accessed: 18 August 2025."},{"key":"830_CR253","unstructured":"Handbook on adult vaccination in Singapore. 2023. https:\/\/www.cfps.org.sg\/assets\/Circulars\/2023\/SG-SID-001-Handbook-v15-Highres-bleed.pdf Accessed: 18 August 2025."},{"key":"830_CR254","doi-asserted-by":"publisher","first-page":"698","DOI":"10.15585\/mmwr.mm6832a3","volume":"68","author":"E Meites","year":"2019","unstructured":"Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2019;68:698\u2013702.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"830_CR255","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s10875-024-01810-w","volume":"45","author":"S Fekrvand","year":"2024","unstructured":"Fekrvand S, Abolhassani H, Esfahani ZH, Fard NNG, Amiri M, Salehi H, et al. Cancer trends in inborn errors of immunity: a systematic review and meta-analysis. J Clin Immunol. 2024;45(1):34.","journal-title":"J Clin Immunol"},{"key":"830_CR256","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s10875-019-00642-3","volume":"39","author":"L P\u00f6yh\u00f6nen","year":"2019","unstructured":"P\u00f6yh\u00f6nen L, Bustamante J, Casanova JL, Jouanguy E, Zhang Q. Life-threatening infections due to live-attenuated vaccines: early manifestations of inborn errors of immunity. J Clin Immunol. 2019;39:376\u201390.","journal-title":"J Clin Immunol"},{"key":"830_CR257","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1086\/517952","volume":"28","author":"M Kamboj","year":"2007","unstructured":"Kamboj M, Sepkowitz KA. Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient. Infect Control Hosp Epidemiol. 2007;28:702\u20137.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"830_CR258","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S1473-3099(08)70231-7","volume":"8","author":"EJ Anderson","year":"2008","unstructured":"Anderson EJ. Rotavirus vaccines: viral shedding and risk of transmission. Lancet Infect Dis. 2008;8:642\u20139.","journal-title":"Lancet Infect Dis"},{"key":"830_CR259","unstructured":"The Green book Chap. 6: Contraindications and special considerations. 2017. https:\/\/assets.publishing.service.gov.uk\/media\/5a82ce28e5274a2e8ab5970f\/Greenbook_chapter_6.pdf Accessed: 15 April 2025."}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-025-00830-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12941-025-00830-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-025-00830-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:05:40Z","timestamp":1761746740000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-025-00830-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":259,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["830"],"URL":"https:\/\/doi.org\/10.1186\/s12941-025-00830-7","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}